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Summary of findings {#CD012994-sec1-0001}
===================

Summary of findings for the main comparisonOral ivermectin 200 μg/kg (1 to 3 doses) compared to topical permethrin 5% cream (1 to 3 applications)**Oral ivermectin 200 μg/kg (1 to 3 doses) compared to topical permethrin 5% cream (1 to 3 applications) for treating scabiesPatient or population:** people with scabies, 2 to 80 years of age **Location:** India, Pakistan **Intervention:** oral ivermectin 200 μg/kg **Comparison:** topical permethrin 5% cream**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with permethrin 5% creamRisk with ivermectin 200 μg/kg**Complete clearance ‐ week 1654 per 1000425 per 1000 (353 to 510)RR 0.65 (0.54 to 0.78)613 (6 RCTs)^1^⊕⊕⊝⊝ LOW^2,3^‐Complete clearance ‐ week 2744 per 1000677 per 1000 (565 to 804)RR 0.91 (0.76 to 1.08)459 (5 RCTs)^4^⊕⊕⊝⊝ LOW^2,5^In 1 study non‐responders were re‐treated after 1 week; in 1 study 44.44% of participants (IVER) and 17.86% of participants (PER) were re‐treated after 1 week (absolute numbers are unclear).Complete clearance ‐ week 4 ‐ IVER 1 dose versus PER 1 application900 per 1000900 per 1000 (774 to 1000)RR 1.00 (0.86 to 1.16)80 (1 RCT)^6^⊕⊕⊕⊕ HIGH‐Complete clearance ‐ week 4 ‐ IVER 1 to 3 doses versus PER 1 to 3 applications932 per 1000857 per 1000 (764 to 959)RR 0.92 (0.82 to 1.03)581 (5 RCTs)^7^⊕⊕⊝⊝ LOW^2,8^In 3 studies non‐responders were re‐treated once; in 1 study non‐responders were re‐treated after 2 and/or 3 weeks (absolute numbers are unclear); in 1 study 12 participants (IVER) and 1 participant (PER) were re‐treated after 2 weeks.Complete clearance ‐ week 4 ‐ IVER 2 doses versus PER 1 application900 per 1000873 per 1000 (747 to 1000)RR 0.97 (0.83 to 1.14)80 (1 RCT)^6^⊕⊕⊕⊕ HIGH‐Number of participants with ≥ 1 AE ‐ week 20 per 10000 per 1000 (0 to 0)Not estimable55 (1 RCT)^9^⊕⊕⊕⊝ MODERATE^2^0 events; 44.44% of participants (IVER) and 17.86% of participants (PER) were re‐treated after 1 week (absolute numbers are unclear)Number of participants with ≥ 1 AE ‐ week 439 per 100051 per 1000 (14 to 190)RR 1.30 (0.35 to 4.83)502 (4 RCTs)^10^⊕⊕⊝⊝ LOW^2,11^In 1 study non‐responders were re‐treated after 2 weeks; in 1 study non‐responders were re‐treated after 2 and 3 weeks; in 1 study participants in IVER group were re‐treated (absolute numbers are unclear).Withdrawal due to AE ‐ week 4See commentSee comment‐305 (3 RCTs)^12^⊕⊕⊕⊝ MODERATE^2^0 events; in 1 study non‐responders were re‐treated after 1 week (absolute numbers are unclear); in 1 study 12 participants (IVER) and 1 participant (PER) were re‐treated after 2 weeks\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: AE:** adverse event; **CI:** confidence interval; **IVER:** ivermectin; **PER:** permethrin; **RCT:** randomized controlled trial; **RR:** risk ratio.**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^2]

Summary of findings 2Oral ivermectin 200 μg/kg (1 to 2 doses) compared to topical permethrin 5% lotion (1 to 5 applications)**Oral ivermectin 200 μg/kg (1 to 2 doses) compared to topical permethrin 5% lotion (1 to 5 applications) for treating scabiesPatient or population:** people with scabies, 5 to 60 years of age **Location:** Egypt, Pakistan **Intervention:** oral ivermectin 200 μg/kg **Comparison:** topical permethrin 5% lotion**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with permethrin 5% lotionRisk with ivermectin 200 μg/kg**Complete clearance ‐ week 1 ‐ IVER 1 dose versus PER 1 application733 per 1000682 per 1000 (543 to 858)RR 0.93 (0.74 to 1.17)120 (1 RCT)^1^⊕⊕⊕⊝ MODERATE^2^‐Complete clearance ‐ week 1 ‐ IVER 1 dose versus PER on 5 consecutive nights593 per 1000415 per 1000 (279 to 610)RR 0.70 (0.47 to 1.03)107 (1 RCT)^3^⊕⊕⊝⊝ LOW^2,4^‐Complete clearance ‐ week 2 ‐ IVER 1 dose versus PER 1 application667 per 1000667 per 1000 (520 to 860)RR 1.00 (0.78 to 1.29)120 (1 RCT)^1^⊕⊕⊝⊝ LOW ^2,4^‐Complete clearance ‐ week 2 ‐ IVER 2 doses versus PER on 5 consecutive nights815 per 1000790 per 1000 (660 to 953)RR 0.97 (0.81 to 1.17)107 (1 RCT)^3^⊕⊕⊕⊝ MODERATE^2^‐Number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus PER on 5 consecutive nights0 per 10000 per 1000 (0 to 0)RR 5.00 (0.25 to 101.58)100 (1 RCT)^1^⊕⊝⊝⊝ VERY LOW ^2,5^‐Withdrawal due to AE ‐ week 2 ‐ IVER 1 dose versus PER 1 application0 per 10000 per 1000 (0 to 0)Not estimable120 (1 RCT)^1^⊕⊕⊕⊝ MODERATE^2^0 events\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).\
**Abbreviations: AE:** adverse event; **CI:** confidence interval; **IVER:** ivermectin; **PER:** permethrin; **RCT:** randomized controlled trial; **RR:** risk ratio**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^3]

Summary of findings 3Oral ivermectin 200 μg/kg (1 to 3 doses) compared to topical ivermectin 1% lotion/solution (1 to 3 applications)**Oral ivermectin 200 μg/kg (1 to 3 doses) compared to topical ivermectin 1% lotion/solution (1 to 3 applications) for treating scabiesPatient or population:** people with scabies, 5 to 80 years of age **Location:** Egypt, India **Intervention:** oral ivermectin 200 μg/kg **Comparison:** topical ivermectin 1% lotion/solution**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with ivermectin 1% lotion/solutionRisk with ivermectin 200 μg/kg**Complete clearance ‐ week 1875 per 1000735 per 1000 (569 to 945)RR 0.84 (0.65 to 1.08)62 (1 RCT)^1^⊕⊕⊝⊝ LOW^2,3^‐Complete clearance ‐ week 21000 per 10001000 per 1000 (940 to 1000)RR 1.00 (0.94 to 1.06)62 (1 RCT)^1^⊕⊕⊕⊝ MODERATE^2^8 participants (oral IVER) and 4 participants (topical IVER) were re‐treated after 1 week.Complete clearance ‐ week 4971 per 1000961 per 1000 (922 to 1000)RR 0.99 (0.95 to 1.03)272 (2 RCTs)^1,4^⊕⊕⊕⊝ MODERATE^2^In 1 study 8 participants (oral IVER) and 4 participants (topical IVER) were re‐treated after 1 week; in 1 study non‐responders were re‐treated after 2 and/or 3 weeks (absolute numbers are unclear).Number of participants with ≥ 1 AE ‐ week 40 per 10000 per 1000 (0 to 0)RR 5.05 (0.25 to 103.87)201 (1 RCT)^4^⊕⊝⊝⊝ VERY LOW^2,5^Non‐responders were re‐treated after 2 and/or 3 weeks (absolute numbers are unclear).Withdrawal due to AE ‐ week 40 per 10000 per 1000 (0 to 0)Not estimable62 (1 RCT)^4^⊕⊕⊕⊝ MODERATE^2^0 events; 8 participants (oral IVER) and 4 participants (topical IVER) were re‐treated after 1 week.\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations:** AE: adverse event; CI: confidence interval; IVER: ivermectin; RCT: randomized controlled trial; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^4]

Summary of findings 4Topical ivermectin 1% lotion (1 to 3 applications) compared to topical permethrin 5% cream (1 to 3 applications)**Topical ivermectin 1% lotion (1 to 3 applications) compared to topical permethrin 5% cream (1 to 3 applications) for treating scabiesPatient or population:** people with scabies, 5 to 80 years of age **Location:** India **Intervention:** topical ivermectin 1% lotion **Comparison:** topical permethrin 5% cream**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with permethrin 5% creamRisk with ivermectin 1% lotion**Complete clearance ‐ week 4943 per 1000962 per 1000 (905 to 1000)RR 1.02 (0.96 to 1.08)210 (1 RCT)^1^⊕⊕⊕⊝ MODERATE^2^Non‐responders were re‐treated after 2 and/or 3 weeks (absolute numbers are unclear).Number of participants with ≥ 1 AE ‐ week 410 per 10003 per 1000 (0 to 80)RR 0.33 (0.01 to 7.93)200 (1 RCT)^1^⊕⊝⊝⊝ VERY LOW^2,3^Non‐responders were re‐treated after 2 and/or 3 weeks (absolute numbers are unclear).\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations:** AE: adverse event; CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^5]

Summary of findings 5Oral ivermectin 200 μg/kg (1 dose) compared to oral ivermectin 200 μg/kg (2 doses)**Oral ivermectin 200 μg/kg (1 dose) compared to oral ivermectin 200 μg/kg (2 doses) for treating scabiesPatient or population:** people with scabies, over 5 years of age **Location:** India **Intervention:** oral ivermectin 200 μg/kg 1 dose **Comparison:** oral ivermectin 200 μg/kg 2 doses**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with ivermectin 200 μg/kg 2 dosesRisk with ivermectin 200 μg/kg 1 dose**Complete clearance ‐ week 4900 per 1000873 per 1000 (747 to 1000)RR 0.97 (0.83 to 1.14)80 (1 RCT)^1^⊕⊕⊕⊕ HIGH‐\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.[^6]

Background {#CD012994-sec1-0002}
==========

This section is based on [@CD012994-bbs2-0088]*.*

Description of the condition {#CD012994-sec2-0001}
----------------------------

Scabies is an intensely itchy parasitic infection of the skin that is caused by the *Sarcoptes scabiei* mite. It occurs worldwide, but is particularly problematic in areas of poor sanitation, overcrowding, and social disruption. The global prevalence of scabies ranges from 0.2% to 71.4%, with large variations in geographical region ([@CD012994-bbs2-0078]). Highest scabies prevalence is noted in Pacific and Central/South American regions. Children are particularly affected ([@CD012994-bbs2-0078]); for example, in Germany, infectious disease surveillance data on centralized homes for asylum seekers from 2004 to 2014 revealed 119 outbreaks. Of 615 people diagnosed with an infectious disease, 19% had scabies ([@CD012994-bbs2-0066]). The Global Burden of Disease Study 2015 concluded that 0.21% of all disability‐adjusted life‐years were caused by scabies worldwide ([@CD012994-bbs2-0065]).

In resource‐rich communities, scabies tends to occur in cyclical epidemics, particularly within institutional living situations such as nursing homes ([@CD012994-bbs2-0082]), or the army ([@CD012994-bbs2-0070]; [@CD012994-bbs2-0071]). There is some seasonal variation, with incidence being greater in the winter than in the summer, perhaps related to a tendency of indoor overcrowding, as well as increased mite survival in colder weather ([@CD012994-bbs2-0043]; [@CD012994-bbs2-0060]). In resource‐poor communities, the occurrence pattern is quite different, with the disease being endemic in many areas ([@CD012994-bbs2-0036]). The prevalence of infections in a community is potentially influenced by changes in social attitudes, population movements, wars, misdiagnosis, inadequate treatment, and changes in the immune status of the population. Scabies infestation represents a considerable burden of ill health in many communities, and although the disease is rarely life‐threatening, it causes widespread debilitation and misery ([@CD012994-bbs2-0052]).

The *S scabiei* life cycle begins with the pregnant female laying two to three eggs a day in burrows several millimetres to several centimetres in length in the stratum corneum (outermost layer) of the skin. After about 50 to 72 hours, larvae emerge and make new burrows. They mature, mate, and repeat this 10‐ to 17‐day cycle. Mites usually live for 30 to 60 days ([@CD012994-bbs2-0052]). Mites survive for up to three days outside of the human body ([@CD012994-bbs2-0033]).

Humans are the main reservoir for *S scabiei* var. *hominis* (variety of the mite named to reflect the main host species). Scabies is usually spread person to person via direct skin contact, including sexual contact, though transfer via inanimate objects such as clothing or furnishings is also possible ([@CD012994-bbs2-0059]). The mite can burrow beneath the skin within 2.5 minutes, though around 20 minutes is more usual ([@CD012994-bbs2-0023]). The level of infectiousness of an individual depends in part on the number of mites harboured, which can vary from just a single mite to millions ([@CD012994-bbs2-0036]). Humans can also be transiently infected by the genetically distinct animal varieties of *S scabiei* (for example, var. *canis*), though cross‐infectivity is low ([@CD012994-bbs2-0047]; [@CD012994-bbs2-0085]).

Clinical infection with the scabies mite causes discomfort and often intense itching of the skin, particularly at night, with irritating papular or vesicular eruptions. While infestation with the scabies mite is not life‐threatening, the severe, persistent itch debilitates and depresses people ([@CD012994-bbs2-0052]). The classical sites of infestation are between the fingers, the wrists, axillary areas, female breasts (particularly the skin of the nipples), peri‐umbilical area, penis, scrotum, and buttocks. Infants are usually affected on the face, scalp, palms, and soles of the feet. Much of the itching associated with scabies is a result of the host immune reaction, and symptoms can take several weeks to appear after initial infection in a person exposed to scabies for the first time. Symptoms appear after a much shorter interval (one to two days) after re‐infestation ([@CD012994-bbs2-0024]).

A more severe or 'crusted\' presentation of infestation is associated with extreme incapacity and with disorders of the immune system, such as HIV infection. Clinically this atypical form of scabies presents with a hyperkeratotic dermatosis resembling psoriasis. Lymphadenopathy and eosinophilia can be present, but itching may be unexpectedly mild. People with crusted scabies may harbour millions of mites and are highly infectious ([@CD012994-bbs2-0068]). The dermatological distribution of mites in such people is often atypical (for example, including the head), and treatment in hospital is advised ([@CD012994-bbs2-0036]; [@CD012994-bbs2-0084]).

Complications are few, although secondary bacterial infection of the skin lesions by group A *Streptococcus pyogenes* or *Staphylococcus aureus*, or both, can occur following repeated scratching, particularly in warmer climates ([@CD012994-bbs2-0068]). Secondary infection with group A *Streptococcus* can lead to acute glomerulonephritis, outbreaks of which have been associated with scabies ([@CD012994-bbs2-0052]; [@CD012994-bbs2-0063]; [@CD012994-bbs2-0061]).

### Diagnosis {#CD012994-sec3-0001}

Diagnosis on clinical grounds is usually made based on a history of itching (particularly if contacts are also affected) and the finding of lesions at the classical sites. The diagnosis can in most cases be confirmed by microscopically identifying a mite, egg, or mite faeces in a skin scraping, or by extracting a mite from a burrow ([@CD012994-bbs2-0036]).

Description of the intervention {#CD012994-sec2-0002}
-------------------------------

Various treatments are available for scabies. These include sulfur compounds, benzyl benzoate, crotamiton, hexachlorocyclohexane, malathion, permethrin, and ivermectin. A number of herbal remedies have also been proposed, including tea tree oil, lippia oil, T ointment, and kakawati poultice ([@CD012994-bbs2-0027]; [@CD012994-bbs2-0073]; [@CD012994-bbs2-0022]; [@CD012994-bbs2-0086]; [@CD012994-bbs2-0074]).

In recent years, topical permethrin and oral ivermectin have become the most relevant treatment options for scabies ([@CD012994-bbs2-0026]; [@CD012994-bbs2-0077]).

Topical permethrin 5% was first licensed in 1989 by the US Food and Drug Administration ([@CD012994-bbs2-0040]). It was approved in Germany in October 2004 ([@CD012994-bbs2-0058]; [@CD012994-bbs2-0064]). In low‐ and middle‐income countries such as India, where permethrin was approved for treating scabies in 1995 ([@CD012994-bbs2-0035]), the treatment is considered expensive, while oral ivermectin seems to be cheaper ([@CD012994-bbs2-0012]).

In contrast, oral ivermectin was first approved for the treatment of scabies in France in 2001 ([@CD012994-bbs2-0040]); in the past few years it has been approved in Australia and the Netherlands ([@CD012994-bbs2-0025]; [@CD012994-bbs2-0069]). Oral ivermectin was approved for the treatment of scabies in Germany in February 2016 ([@CD012994-bbs2-0081]), whereas in the USA it is still used off‐label ([@CD012994-bbs2-0034]).

Topical ivermectin has also been investigated for the treatment of scabies in recent years due to the expected therapeutic efficacy. It is not approved for the treatment of scabies, but for treating head lice (0.5% lotion, [@CD012994-bbs2-0049]) and inflammatory lesions of rosacea (1% cream, [@CD012994-bbs2-0050]).

Systemic ivermectin is associated with adverse reactions such as nausea, rash, dizziness, itching, abdominal pain, and fever. Many of these symptoms may be an allergic reaction to the dead parasites rather than to ivermectin itself ([@CD012994-bbs2-0048]). An increased risk of death amongst elderly patients in a long‐term care facility has been reported with the use of ivermectin ([@CD012994-bbs2-0028]). However, the validity of this report has been discussed considerably ([@CD012994-bbs2-0030]; [@CD012994-bbs2-0039]; [@CD012994-bbs2-0042]; [@CD012994-bbs2-0075]), and its findings could not be confirmed by multiple subsequent studies.

Rare adverse reactions have been reported with the use of permethrin, including neck dystonia ([@CD012994-bbs2-0038]), pruritus, burning, and stinging ([@CD012994-bbs2-0048]).

### Prevention {#CD012994-sec3-0002}

Prevention is based on principles common to most infectious diseases, that is limitation of contact with the mite. An infested person can spread scabies even if no symptoms are present. The probability of transmission is highest with direct and close skin‐to‐skin contact and happens most frequently between family members. Linen used and worn three days before the start of treatment should be washed thoroughly to avoid spreading scabies ([@CD012994-bbs2-0033]). Contacts of cases are usually advised to treat themselves at the same time as the case in order to reduce the risk of re‐exposure and re‐infestation ([@CD012994-bbs2-0084]).

How the intervention might work {#CD012994-sec2-0003}
-------------------------------

Ivermectin is a broad‐spectrum anthelmintic agent, which affects the nervous system of the scabies mite and causes its death ([@CD012994-bbs2-0025]). Unlike permethrin, it is not ovicidal. Ivermectin is available as systemic antiscabies drug (200 µg/kg/dose; [@CD012994-bbs2-0034]). Permethrin is usually available as a 5% cream or 5% lotion. It is a synthetic pyrethroid, which kills the scabies mite and the eggs ([@CD012994-bbs2-0034]).

In general, permethrin is applied as 5% cream to all areas of the body from head/neck to toe. It is left on overnight or up to 24 hours and then rinsed off. Application is sometimes repeated once, about one to two weeks later. Children aged two months or older can also be treated ([@CD012994-bbs2-0040]; [@CD012994-bbs2-0026]; [@CD012994-bbs2-0032]; [@CD012994-bbs2-0084]; [@CD012994-bbs2-0034]; [@CD012994-bbs2-0080]).

Ivermectin is taken orally as a tablet with a dosage of 200 µg/kg body weight, usually once but sometimes a second time after one to two weeks. It has not been tested in pregnant or lactating woman and children weighing less than 15 kg. Furthermore, opinions diverge on whether the tablet should be taken with food or on an empty stomach ([@CD012994-bbs2-0040]; [@CD012994-bbs2-0026]; [@CD012994-bbs2-0032]; [@CD012994-bbs2-0084]; [@CD012994-bbs2-0034]; [@CD012994-bbs2-0080]).

A follow‐up visit to determine whether the patient is cured should ideally occur one month after the initiation of treatment. This time allows for lesions to heal and for any eggs and mites to reach maturity in case the treatment did not work (that is, beyond the longest incubation interval). Patients should be advised that itching may persist for one to two weeks after treatment, even if the mite is successfully eradicated ([@CD012994-bbs2-0031]). Because of this delay in symptom relief, it may sometimes be difficult to distinguish re‐infestation from primary treatment failure.

Why it is important to do this review {#CD012994-sec2-0004}
-------------------------------------

Apart from a non‐Cochrane systematic review that considered several scabies treatments ([@CD012994-bbs2-0044]), there is currently no systematic review focusing on the available evidence comparing ivermectin with permethrin. Using data from randomized controlled trials, this review summarizes and evaluates the existing evidence on the efficacy and safety of permethrin and ivermectin for scabies. We aimed to answer the following questions in relation to safety and efficacy.

Is oral ivermectin superior to topical permethrin?Is oral ivermectin superior to topical ivermectin?Is topical ivermectin superior to topical permethrin?Is a single dose of oral ivermectin superior to multiple doses of oral ivermectin?

Global epidemics and an increasing number of asylum seekers due to the Middle Eastern population migration highlights the importance of this review to investigate and understand scabies interventions ([@CD012994-bbs2-0066]; [@CD012994-bbs2-0029]).

A Cochrane Review on 'Interventions for treating scabies\' was published in 2007 ([@CD012994-bbs2-0088]). This includes an evaluation of crotamiton, lindane, sulfur, and benzyl benzoate; [@CD012994-bbs2-0088] and earlier published versions are listed in the '[Other published versions of this review](#CD012994-bbs1-0005){ref-type="ref-list"}\' section.

Objectives {#CD012994-sec1-0003}
==========

To assess the efficacy and safety of topical permethrin and topical or systemic ivermectin for scabies in people of all ages.

Methods {#CD012994-sec1-0004}
=======

Criteria for considering studies for this review {#CD012994-sec2-0005}
------------------------------------------------

### Types of studies {#CD012994-sec3-0003}

We only included randomized controlled trials (RCTs). We considered all study reports irrespective of their publication status and language of publication.

The review protocol was registered with PROSPERO International prospective register of systematic reviews in October 2016 ([@CD012994-bbs2-0087]). Very few changes have been made to the proposed methods; see the '[Differences between protocol and review](#CD012994-sec1-0016){ref-type="notes"}\' section.

### Types of participants {#CD012994-sec3-0004}

Children or adults of both sexes with a diagnosis of classical scabies, as defined by the study authors.

### Types of interventions {#CD012994-sec3-0005}

#### Intervention {#CD012994-sec4-0001}

Topical permethrin.Topical ivermectin.Systemic ivermectin.

#### Control {#CD012994-sec4-0002}

One of the above mentioned interventions.

### Types of outcome measures {#CD012994-sec3-0006}

#### Primary outcomes {#CD012994-sec4-0003}

Complete clearance (outcome assessment at 7, 14, and 30 days\' post‐initiation of treatment).

#### Secondary outcomes {#CD012994-sec4-0004}

Number of people re‐treated.Number of people with at least one adverse event (outcome assessment at the end of active study period).Number of people withdrawn from study due to adverse event (outcome assessment at the end of active study period).

Search methods for identification of studies {#CD012994-sec2-0006}
--------------------------------------------

We attempted to identify all RCTs regardless of language or publication status (published, unpublished, in press, or in progress).

### Electronic searches {#CD012994-sec3-0007}

#### Databases {#CD012994-sec4-0005}

We searched the following databases up to 25 April 2017 using the search terms and strategy described in [Appendix 1](#CD012994-sec2-0016){ref-type="app"}: the Cochrane Infectious Disease Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL, published in the Cochrane Library; Issue 4, 2017); MEDLINE (PubMed, from 1946); Embase Ovid (from 1974); LILACS (Latin American and Caribbean Center on Health Sciences Information) ([lilacs.bvsalud.org/](lilacs.bvsalud.org/), from 1982), and IndMED ([indmed.nic.in/](indmed.nic.in/), from 1985). We also searched EconLit (Economic Literature database, EBSCOHost, from 1993 to 26 July 2016) and ERIC (Education Resources Information Center, EBSCOHost, from 1966 to 26 July 2016).

#### Grey literature {#CD012994-sec4-0006}

We searched the following sources for published and unpublished trials up to 26 July 2016:

British Library Index of Conference Proceedings ([explorecatalogue.bl.uk/](explorecatalogue.bl.uk/)), search term: \"scabies\" AND (\"trial\" OR \"study\" OR \"treatment\");British Library for Development Studies ([blds.ids.ac.uk/](blds.ids.ac.uk/)), search term: \"scabies\";BRIDGE ([www.bridge.ids.ac.uk/](www.bridge.ids.ac.uk/)), search term: \"scabies\";Social Care Online ([www.scie‐socialcareonline.org.uk/](www.scie‐socialcareonline.org.uk/)), search term: \"scabies\";Institute for Development Studies ([www.ids.ac.uk/search](www.ids.ac.uk/search)), search term: \"scabies\";IIED ([www.iied.org/](www.iied.org/)), search term: \"scabies\"; andScience.gov ([www.science.gov/](www.science.gov/)), search term: \"scabies\" AND (\"trial\" OR \"study\" OR \"treatment\").

#### Trials registers {#CD012994-sec4-0007}

We searched the following sources for registered trials using the term \"scabies\" up to 25 April 2017:

World Health Organization International Clinical Trials Registry Platform (WHO ICTRP, [apps.who.int/trialsearch](apps.who.int/trialsearch));ISRCTN registry ([www.isrctn.com](www.isrctn.com));CenterWatch Clinical Trials Listing ([www.centerwatch.com](www.centerwatch.com));US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov ([www.clinicaltrials.gov](www.clinicaltrials.gov));TrialsCentral ([www.trialscentral.org](www.trialscentral.org)); andUK Department of Health National Research Register ([www.nihr.ac.uk](www.nihr.ac.uk)).

### Searching other resources {#CD012994-sec3-0008}

#### Reference lists {#CD012994-sec4-0008}

We scanned the reference lists of all included RCTs for further studies.

#### Correspondence {#CD012994-sec4-0009}

We attempted to obtain unpublished data via e‐mail correspondence with first authors if contact details were available or could be identified.

Data collection and analysis {#CD012994-sec2-0007}
----------------------------

Several of the following sections may be identical to parts of the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD012994-bbs2-0062]).

### Selection of studies {#CD012994-sec3-0009}

Two review authors independently screened the titles and abstracts of all studies identified by the search to determine those that were potentially relevant. The full texts of all records assessed as eligible by at least one of the review authors were obtained. We read all available full texts to assess study eligibility according to the inclusion criteria.

We scrutinized the trial reports to ensure that multiple publications from the same trial were identified so that data were only included once (see the [Characteristics of included studies](#CD012994-sec2-0022){ref-type="sec"} table). Reasons for the exclusion of studies during the full‐text screening phase are listed in the [Characteristics of excluded studies](#CD012994-sec2-0023){ref-type="sec"} table.

We illustrated the study selection process in a PRISMA flow diagram.

### Data extraction and management {#CD012994-sec3-0010}

Two review authors (SR and CD) independently extracted data from the included trial reports using a standardized data extraction form (Microsoft Word). Items extracted include study characteristics, inclusion and exclusion criteria, baseline data, definition of outcomes, adverse events, and whether participants were re‐treated. The form was piloted.

We extracted the number of participants randomized as well as the number of participants analysed for each study arm. For each dichotomous outcomes, we recorded the number of participants experiencing the event in each arm of the trial. If efficacy data were not reported using an intention‐to‐treat approach, we imputed these data employing a non‐responder imputation approach for all intervention and control groups.

Where primary or secondary outcomes were measured at more than one time point, we aimed to extract all relevant data corresponding to 7, 14, and 30 days post‐treatment initiation.

For one study, [@CD012994-bbs2-0013], we extracted percentages of participants achieving 'complete clearance of lesions\' (graded as good improvement) from a graph using the Engauge Digitizer software ([@CD012994-bbs2-0046]). We converted the percentages into absolute numbers, as no withdrawals or dropouts were reported.

After comparing the extracted data and resolving any differences through discussion, one review author (SR) entered the data into Review Manager 5 (RevMan 5) ([@CD012994-bbs2-0076]), and a second review author (CD) checked the data for accuracy.

### Assessment of risk of bias in included studies {#CD012994-sec3-0011}

For each included study, two review authors independently assessed the methodological quality using the Cochrane 'Risk of bias\' assessment tool ([@CD012994-bbs2-0062]). We assessed the following seven domains.

Random sequence generation.Allocation concealment.Blinding of participants and personnel.Blinding of outcome assessment.Completeness of outcome data.Selective reporting.Other sources of bias.

For each trial, to assess 'selection bias\' we described the methods used to generate the randomization list and how the allocation was concealed; to assess 'performance and detection bias\' we stated who was blinded and, if reported, how this was done. In order to assess 'attrition bias\', we reported the number of participants lost to follow‐up and the method study authors used to deal with missing data. If more than 10% of the participants were lost to follow‐up in at least one of the study groups, and no imputation method was used to analyse the study outcomes, we evaluated the risk of bias as high. To assess 'reporting bias\', we described any discrepancies between the methods section (planned measurements) and the results as reported in the included records. For the domain 'other bias\', we have listed and assessed any other potential sources of bias that may have influenced the studies\' results.

For each of the domains 'selection bias\', 'reporting bias\', and 'other bias\', we made one assessment ('low risk\', 'high risk\', or 'unclear risk\' of bias). For the domains 'performance bias\', 'detection bias\', and 'attrition bias\', we made two assessments: one for all efficacy outcomes and one for all safety outcomes per study. Discrepancies in assessments were resolved by discussion.

Review authors\' judgements about each 'Risk of bias\' item for each included study are presented in the 'Risk of bias\' summary figure.

### Measures of treatment effect {#CD012994-sec3-0012}

We presented results as risk ratios (RRs) with corresponding 95% confidence intervals (CIs). If an outcome was positive (for example, clearance), RRs greater than one demonstrate a favourable outcome of the intervention of interest, and these were presented to the right of the line of no effect. In case of negative outcomes (for example, safety), RRs smaller than one demonstrate a favourable outcome of the intervention of interest (represented to the left of the line of no effect). We expressed all statistically significant results as numbers needed to treat for an additional beneficial outcome (NNTB) with 95% CIs ([@CD012994-bbs2-0037]).

To avoid the problem of multiplicity, we chose only one primary outcome and a limited number of secondary outcomes.

### Unit of analysis issues {#CD012994-sec3-0013}

To avoid unit of analysis errors, we included every study only once in each comparison (for each outcome at each time point). We also used this approach for multi‐arm studies given that for each comparison a single effect measure was calculated. This precluded the same group of participants being included more than once in the same meta‐analysis.

In one comparison, we combined two arms of a three‐arm study for the outcome 'complete clearance\' ([@CD012994-bbs2-0012]). In both arms oral ivermectin 200 μg/kg body weight was administered on day one. After two weeks, participants in one of these arms received an additional dose of oral ivermectin. We considered both arms as treated equally and hence combined the number of events and participants when assessing the outcome after one and two weeks of treatment.

### Dealing with missing data {#CD012994-sec3-0014}

For dichotomous efficacy data, we performed an intention‐to‐treat analysis. We imputed outcome data for the missing participants using a non‐responder imputation approach for the intervention and the control groups, meaning that we assumed treatment failure for all missing participant data (conservative approach, [@CD012994-bbs2-0062]). Participants were analysed in the group to which they had been randomized. We specified the amount of imputed participant data as footnotes in the forest plots.

Some study authors reported insufficient information on safety outcomes. In such cases we reported data as presented by the study authors.

If there were inconsistencies within a publication regarding the reported data, we asked the author for clarification. We sent two e‐mails if contact details were provided in the publication or if we were able to identify them elsewhere.

### Assessment of heterogeneity {#CD012994-sec3-0015}

We assessed heterogeneity by visually inspecting forest plots, calculating an I² statistic, and carrying out a Chi² test for heterogeneity using RevMan 5 ([@CD012994-bbs2-0076]). If we detected heterogeneity (that is, I² statistic \> 50%), we undertook subgroup or sensitivity analysis, or both, to explore the causes of the heterogeneity ([@CD012994-bbs2-0062]).

If heterogeneity was low or not detected, we pooled results from trials using a random‐effects meta‐analysis model, because we anticipated that the different studies would estimate different intervention effects ([@CD012994-bbs2-0041]; [@CD012994-bbs2-0062]).

### Assessment of reporting biases {#CD012994-sec3-0016}

Had we included 10 or more studies comparing the same intervention, we would have evaluated a funnel plot. However, this was not the case, and we were unable to assess publication bias. We aimed at avoiding the introduction of other types of reporting bias at the systematic review level by conducting extensive searches and including all languages.

### Data synthesis {#CD012994-sec3-0017}

We have summarized and presented qualitative information (for example, study design, description of participants, study groups, outcome measurements) in the [Characteristics of included studies](#CD012994-sec2-0022){ref-type="sec"} tables. We calculated RRs and 95% CIs using Review Manager 5 for each of the preselected outcomes and pooled data using a random‐effects model if appropriate ([@CD012994-bbs2-0076]).

Where a meta‐analysis could not be performed (for example, due to effects being reported as percentages only), we described the results in the text.

#### 'Summary of findings\' tables {#CD012994-sec4-0010}

For each assessed comparison we created a 'Summary of findings\' table, which included an evaluation of the certainty of evidence according to the GRADE approach described in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD012994-bbs2-0062]; [@CD012994-bbs2-0083]). Using the online tool GRADEpro GDT, we assessed the certainty of the evidence as either high, moderate, low, or very low ([@CD012994-bbs2-0051]). Randomized controlled trials start as high‐certainty evidence and are rated down depending on the presence of study limitations (risk of bias), inconsistency, indirectness, imprecision, and publication bias.

##### Risk of bias {#CD012994-sec5-0001}

If most of the information was from studies with an overall assessment of moderate or high risk of bias, we downgraded one (serious limitations) or two levels (very serious limitations) ([@CD012994-bbs2-0053]).

##### Inconsistency {#CD012994-sec5-0002}

We judged large and unexplained inconsistency based on similarity of point estimates and the extent of overlap of CIs. Depending on the magnitude of inconsistency in study results, we rated down by one or two levels ([@CD012994-bbs2-0056]).

##### Imprecision {#CD012994-sec5-0003}

We examined 95% CI for imprecision. If the confidence limit crossed the minimal clinically important difference thresholds, we downgraded one level. Minimal important difference represents the smallest difference between treatment groups for an outcome that clinicians or patients identify as meaningful. By default, these thresholds are 0.75 for appreciable harm and 1.25 for appreciable benefit. If both thresholds were crossed and CIs were wide, we downgraded the certainty by two levels ([@CD012994-bbs2-0055]).

##### Indirectness {#CD012994-sec5-0004}

We assessed differences in patient populations, (co‐)interventions, and measurement of the outcomes of the pooled studies. Depending on the extent of differences, we downgraded one or two levels ([@CD012994-bbs2-0057]).

##### Publication bias {#CD012994-sec5-0005}

Due to the small number of studies pooled, it was inappropriate to evaluate a funnel plot. We rated the likelihood of publication bias based on study size and sponsorship. In case of publication bias, we rated down by one level ([@CD012994-bbs2-0054]).

We justified and documented our assessment in the 'Summary of findings\' tables (that is, in case of downgrading) using footnotes.

### Subgroup analysis and investigation of heterogeneity {#CD012994-sec3-0018}

Due to the different study designs with respect to drug dosing, we analysed subgroups according to the number of treatment doses ‐ one, one to two, or two doses ‐ for ivermectin 200 μg/kg body weight compared to permethrin 5% cream (for the outcome 'complete clearance\' assessed after four weeks of treatment).

We investigated statistical heterogeneity by means of sensitivity analysis.

### Sensitivity analysis {#CD012994-sec3-0019}

For two comparisons and outcomes, we conducted sensitivity analyses due to statistical heterogeneity. We could not identify meaningful groups of studies based on 'Risk of bias\' assessments that would help explain the heterogeneity. We reported effect estimates excluding studies with slightly different treatment schemes or with a contrary result, separately (see [Appendix 2](#CD012994-sec2-0017){ref-type="app"}).

Results {#CD012994-sec1-0005}
=======

Description of studies {#CD012994-sec2-0008}
----------------------

### Results of the search {#CD012994-sec3-0020}

The electronic searches (see [Electronic searches](#CD012994-sec3-0007){ref-type="sec"}) retrieved 692 references. We found another article coincidentally through a search of the Internet, which we included.

We screened the titles and abstracts of 441 records retrieved through database searches and assessed 19 full‐text records for eligibility.

We screened the reference lists of already included trials and found three more potentially relevant studies, two of which met the inclusion criteria.

A total of 15 trials met the inclusion criteria of the review.

Trial register searches identified 17 further studies (including two duplicates); we could include one ongoing trial.

The study selection process can be seen in [Figure 1](#CD012994-fig-0001){ref-type="fig"}.Figure 1Study flow diagram.

### Included studies {#CD012994-sec3-0021}

We included 15 RCTs that investigated 1896 participants treated with ivermectin or permethrin. Details of all included studies are provided in the [Characteristics of included studies](#CD012994-sec2-0022){ref-type="sec"} tables.

We contacted the authors of six studies to obtain missing data or to clarify inconsistent information ([@CD012994-bbs2-0005]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]); the authors of two studies replied ([@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]). Details are reported in the respective [Characteristics of included studies](#CD012994-sec2-0022){ref-type="sec"} tables.

#### Design {#CD012994-sec4-0011}

All included studies were parallel‐group RCTs, and most were conducted as open‐label trials. Participants and personnel were blinded to treatment assignment in only one study ([@CD012994-bbs2-0012]). In a second study, the outcome assessor was blinded ([@CD012994-bbs2-0011]).

We assumed that all studies recruited participants from one centre, but this was not stated clearly in all study reports.

Seven studies compared two treatment groups. Five of these studies evaluated topical permethrin and systemic ivermectin ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]); one study compared topical ivermectin with systemic ivermectin ([@CD012994-bbs2-0002]); and the remaining study compared one versus three treatments of systemic ivermectin ([@CD012994-bbs2-0006]).

Five studies compared three treatment groups. One study investigated permethrin, systemic ivermectin, and topical ivermectin ([@CD012994-bbs2-0004]); one study compared permethrin with two different regimens of systemic ivermectin ([@CD012994-bbs2-0012]); and the remaining three studies investigated systemic ivermectin and permethrin as well as another treatment not addressed in this review (benzyl benzoate 25% lotion ([@CD012994-bbs2-0003]); gamma benzene hexachloride 1% lotion ([@CD012994-bbs2-0008]); combination of topical permethrin and systemic ivermectin ([@CD012994-bbs2-0015])).

Three studies compared four treatment groups. [@CD012994-bbs2-0001] investigated topical permethrin and systemic ivermectin (plus two groups treated with sulfur ointment or benzyl benzoate cream not included in this review). [@CD012994-bbs2-0005] also examined the effect of gamma benzene hexachloride 1% and included a placebo group. [@CD012994-bbs2-0007] investigated topical permethrin and systemic ivermectin (plus two groups treated with gamma benzene hexachloride 1% lotion or benzyl benzoate 20% lotion not included in this review).

In two studies, uncured participants were switched to another treatment ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0004]).

The oldest included study was conducted from 1993 to 1995 and was published in 1996 ([@CD012994-bbs2-0006]), while the three most recent ones were published in 2016 ([@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]; [@CD012994-bbs2-0015]).

#### Sample sizes {#CD012994-sec4-0012}

The sample size varied from 62, in [@CD012994-bbs2-0002], to 315, in [@CD012994-bbs2-0004]. In two studies the numbers of randomized participants per study group were not reported ([@CD012994-bbs2-0009]; [@CD012994-bbs2-0014]).

#### Study settings {#CD012994-sec4-0013}

All studies took place in dermatological outpatient clinics/dermatological departments of medical colleges or hospitals.

#### Age {#CD012994-sec4-0014}

Eleven studies included children and adults, with an age range of two to 80 years ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]; [@CD012994-bbs2-0015]).

[@CD012994-bbs2-0011] included only adults aged 18 to 60. One trial enrolled only children from five to 15 years of age ([@CD012994-bbs2-0010]).

Only three studies reported the mean age at baseline of all included participants. In the study by [@CD012994-bbs2-0001], the mean age of the 200 participants who completed the study was 25.33 years (standard deviation (SD) 12.84). The mean age at baseline of the 62 randomized participants in the study by [@CD012994-bbs2-0002] was 21.8 years (SD 15). [@CD012994-bbs2-0006] did not report the age of participants, but stated a mean age of 12 and 16 years for male and female participants, respectively, in the group treated with one dose of ivermectin 250 μg/kg body weight, and a mean age of 18 and 20 for male and female participants, respectively, in the three‐dose group.

Another study by [@CD012994-bbs2-0014], which was available only as an abstract, did not report age.

#### Sex {#CD012994-sec4-0015}

All studies recruited both women and men. Eleven studies reported the proportion of female participants, including 639 women (45.22%) and 774 men ([@CD012994-bbs2-0006]; [@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]; [@CD012994-bbs2-0015]).

#### Geographical region {#CD012994-sec4-0016}

Ten studies were conducted in India ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0015]), two in Pakistan ([@CD012994-bbs2-0009]; [@CD012994-bbs2-0011]), two in Egypt ([@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]), and one in Mexico ([@CD012994-bbs2-0006]).

#### Diagnosis of scabies {#CD012994-sec4-0017}

A detailed description of how scabies was diagnosed in each study is provided as part of the [Characteristics of included studies](#CD012994-sec2-0022){ref-type="sec"} tables.

Diagnostic procedures differed greatly. In six studies clinical diagnosis was confirmed by microscopic examination ([@CD012994-bbs2-0005]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]). In the study by [@CD012994-bbs2-0015], participants were included based on clinical criteria, even when the microscopic examination was negative. In four studies scabies was diagnosed clinically only ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0008]). In the study by [@CD012994-bbs2-0009], only in cases of uncertainty confirmation of the clinical diagnosis was sought by an additional microscopic examination. Three studies did not report diagnostic procedures ([@CD012994-bbs2-0006]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]).

#### Interventions {#CD012994-sec4-0018}

##### Treatment duration, frequency, and formulation {#CD012994-sec5-0006}

The treatment frequency of permethrin ranged from a single application in most included studies ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0015]), to a single application daily on five days/nights in a row ([@CD012994-bbs2-0001]). In one study, permethrin was applied on day one and again after one week ([@CD012994-bbs2-0008]).

Most of the included studies administered permethrin as a 5% cream ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0015]). Two studies investigated permethrin as a lotion ([@CD012994-bbs2-0001]: 5% for adults, 2.5% for children and [@CD012994-bbs2-0011]: 5%). One study, available as an abstract only, did not report the galenic formulation ([@CD012994-bbs2-0014]).

Systemic ivermectin was administered once in 12 studies ([@CD012994-bbs2-0006]; [@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0002]; [@CD012994-bbs2-0015]). In two studies, systemic ivermectin was administered on day one and again one week later ([@CD012994-bbs2-0008]; [@CD012994-bbs2-0001]). In another two studies, two doses of ivermectin ‐ on day one and again after two weeks ‐ were dispensed ([@CD012994-bbs2-0005]; [@CD012994-bbs2-0012]). In [@CD012994-bbs2-0006], ivermectin was given three times: on day one, day seven, and day 10.

Systemic ivermectin was administered orally, in five studies in tablet form ([@CD012994-bbs2-0005]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0015]). The other 10 studies did not specify whether a tablet or a capsule was used ([@CD012994-bbs2-0006]; [@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]).

Two studies investigated a single application of topical ivermectin ([@CD012994-bbs2-0004]; [@CD012994-bbs2-0002]), administered as 1% lotion, in [@CD012994-bbs2-0004], or as 1% solution, in [@CD012994-bbs2-0002].

##### Re‐treatment {#CD012994-sec5-0007}

Most studies did not report the absolute numbers of participants needing re‐treatment or being re‐treated. Only two trials comparing ivermectin with permethrin reported numbers of participants needing a second treatment due to non‐response, which was higher in the systemic ivermectin group than in the permethrin group.

We specified any available information on number of participants re‐treated as footnotes in the forest plots and in [Appendix 3](#CD012994-sec2-0018){ref-type="app"}.

#### Treatment of family members and close contacts {#CD012994-sec4-0019}

In nine studies, members of the family or close contacts, or both, were treated alongside the study participants.

In four studies, family members, [@CD012994-bbs2-0013]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0001], or all contacts of the participants, [@CD012994-bbs2-0011], received the same medication as the study participant.

In three studies, contacts were treated irrespective of the participant\'s treatment as follows: [@CD012994-bbs2-0012] provided all family contacts with topical permethrin 5% cream for single overnight application. [@CD012994-bbs2-0006] treated 95 contacts with an oral single dose of 250 μg/kg body weight ivermectin. [@CD012994-bbs2-0003] gave benzyl benzoate 25% lotion to all participants so family members could be treated simultaneously.

[@CD012994-bbs2-0008] explicitly explained to all participants the importance of treating their family members. Whether medication was dispensed or not was not reported. [@CD012994-bbs2-0002] reported that contacts were treated; the nature and extent of the treatment were not described.

#### Definition and diagnosis of complete clearance {#CD012994-sec4-0020}

Three studies provided no definition of 'clinical cure of scabietic lesions\' ([@CD012994-bbs2-0004]), 'improvement clinically\' ([@CD012994-bbs2-0005]), or 'cure rate\' ([@CD012994-bbs2-0014]). The other studies provided details of the definition and diagnosis of complete clearance, which are given in [Appendix 4](#CD012994-sec2-0019){ref-type="app"}.

### Excluded studies {#CD012994-sec3-0022}

We excluded five studies after full‐text assessment (see [Figure 1](#CD012994-fig-0001){ref-type="fig"}). Reasons for the exclusion of studies are listed in the [Characteristics of excluded studies](#CD012994-sec2-0023){ref-type="sec"} table.

The objective of [@CD012994-bbs2-0016] was a cost‐effectiveness analysis of topical permethrin versus oral ivermectin. The analysis consists of two study groups of [@CD012994-bbs2-0004]. The study did not report any additional relevant data.

We excluded one study on people with crusted scabies, which was not yet open for participant recruitment ([@CD012994-bbs2-0019]). The aim of this study is to assess the efficacy of ivermectin 400 μg/kg body weight compared to ivermectin 200 μg/kg body weight in severe forms of scabies.

We excluded three studies co‐authored by Mohamad Goldust due to suspicion of flawed data ([@CD012994-bbs2-0017]; [@CD012994-bbs2-0018]; [@CD012994-bbs2-0020]). We are aware of several other publications on scabies by Goldust and colleagues. Details are reported elsewhere ([@CD012994-bbs2-0045]). The issue was presented and discussed at the annual meeting of the Cochrane Skin Group on 9‐10 January 2017 in Berlin: a unanimous decision was made to exclude these studies from the review due to the suspicion of flawed data.

#### Ongoing studies {#CD012994-sec4-0021}

One study is still recruiting ([@CD012994-bbs2-0021]), hence results are not yet available.

Risk of bias in included studies {#CD012994-sec2-0009}
--------------------------------

See [Figure 2](#CD012994-fig-0002){ref-type="fig"} for the 'Risk of bias\' evaluations of the included trials. For more details on each assessment, see the 'Risk of bias table\' for each individual study in the [Characteristics of included studies](#CD012994-sec2-0022){ref-type="sec"} tables.Figure 2'Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included trial.

### Allocation {#CD012994-sec3-0023}

More than half of the included studies used adequate methods to generate random sequence ([@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]). The other seven studies did not report the methods used ([@CD012994-bbs2-0006]; [@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0015]).

Four studies reported methods that assured adequate allocation concealment ([@CD012994-bbs2-0003]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0001]). We assessed the remaining 11 studies as at unclear risk of bias ([@CD012994-bbs2-0006]; [@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0002]; [@CD012994-bbs2-0015]).

Consequently, we judged only four out of 15 studies to be at low risk of selection bias ([@CD012994-bbs2-0003]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0001]).

### Blinding {#CD012994-sec3-0024}

We assessed performance and detection bias for efficacy and safety outcomes separately. There were only minor differences. We assessed nearly all included studies as at high risk of performance and detection bias.

Thirteen studies were at high risk of bias with regard to blinding. Of these, seven studies were not blinded ([@CD012994-bbs2-0006]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0015]), and six study authors did not report anything about steps taken to ensure blinding of participants or personnel, or both ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0002]). We assessed [@CD012994-bbs2-0012], which was was double‐blind, as at low risk of performance and detection bias. We assessed [@CD012994-bbs2-0011] as at low risk of bias regarding efficacy outcomes as at least the physician was blinded to treatment assignment (single‐blind study). We rated this study as at high risk of bias regarding adverse events because participants who are aware of their treatment (no blinding) may pay more attention to adverse events related to the specific mode of application (topical versus oral), which introduces bias.

### Incomplete outcome data {#CD012994-sec3-0025}

We assessed attrition bias for efficacy and safety outcomes separately, which led to different assessments in four studies ([@CD012994-bbs2-0005]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0002]).

#### Efficacy outcome {#CD012994-sec4-0022}

In seven studies none or less than 10% of the randomized participants in at least one of the study groups were lost to follow‐up over the duration of the study. We assessed the risk of attrition bias in these studies as low ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]; [@CD012994-bbs2-0015]).

More than 10% of the randomized participants in at least one of the study groups were lost to follow‐up in [@CD012994-bbs2-0003], [@CD012994-bbs2-0009], and [@CD012994-bbs2-0008]. [@CD012994-bbs2-0005] reported results as percentages only; the number of participants evaluated and thus the number of participants eventually lost to follow‐up is unclear. [@CD012994-bbs2-0006] and [@CD012994-bbs2-0014] reported no numerical outcome data, therefore we assessed the risk of bias as high. A clear explanation of the scales or items used to assess the outcome was missing in [@CD012994-bbs2-0007], which led to an assessment of high risk of bias regarding the reported efficacy outcomes.

We rated the remaining study by [@CD012994-bbs2-0004] as at unclear risk of bias because the number of participants lost to follow‐up was less than 10% (15/315), but the number of participants analysed at week two and three was unclear.

#### Safety outcome {#CD012994-sec4-0023}

In six studies, none or less than 10% of the randomized participants in at least one of the study groups were lost to follow‐up. We assessed the risk of attrition bias in these studies as being low ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0015]).

In contrast, more than 10% of the randomized participants in at least one of the study groups were lost to follow‐up in [@CD012994-bbs2-0003], [@CD012994-bbs2-0009], and [@CD012994-bbs2-0008]. No numerical outcome data were reported in [@CD012994-bbs2-0006], [@CD012994-bbs2-0014], and [@CD012994-bbs2-0007]. We rated these six studies as at high risk of attrition bias. We assessed the remaining three studies as at unclear risk of bias. In [@CD012994-bbs2-0005], the number of participants evaluated for safety was unclear. [@CD012994-bbs2-0012] did not report adverse events for each study group separately, and [@CD012994-bbs2-0002] did not report numerical data on participants with adverse events per study group.

### Selective reporting {#CD012994-sec3-0026}

We rated two studies as at high risk of reporting bias. [@CD012994-bbs2-0006] and [@CD012994-bbs2-0008] defined outcomes in the corresponding methods sections but did not report results for these outcomes. We assessed the remaining studies as at unclear risk of reporting bias ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0011]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0001]; [@CD012994-bbs2-0002]; [@CD012994-bbs2-0015]). None of the included studies provided information about a study protocol.

### Other potential sources of bias {#CD012994-sec3-0027}

We judged three studies as at high risk of other sources of bias. [@CD012994-bbs2-0009] and [@CD012994-bbs2-0011] reported baseline differences between intervention and control group. In addition, there were minor inconsistencies in the publications. The reports by [@CD012994-bbs2-0010] revealed discrepancies in response data between the abstract and the doctoral thesis the study author provided. We judged all other included studies to be of unclear risk of other sources of bias.

Effects of interventions {#CD012994-sec2-0010}
------------------------

See: [Table 1](#CD012994-tbl-0001){ref-type="table"}; [Table 2](#CD012994-tbl-0002){ref-type="table"}; [Table 3](#CD012994-tbl-0003){ref-type="table"}; [Table 4](#CD012994-tbl-0004){ref-type="table"}; [Table 5](#CD012994-tbl-0005){ref-type="table"}

See the 'Summary of findings\' tables section.

The included studies investigated the following four comparisons.

Oral ivermectin versus topical permethrin.Oral ivermectin versus topical ivermectin.Topical ivermectin versus topical permethrin.Oral ivermectin versus oral ivermectin in different doses.

Data on the following six comparisons are reported here.

Ivermectin 200 μg/kg body weight (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications).Ivermectin 200 μg/kg body weight (1 to 2 doses) versus permethrin 5% lotion (1 to 5 applications).Ivermectin 200 μg/kg body weight (1 dose) versus permethrin 5% (of unknown ointment base, 1 application).Ivermectin 200 μg/kg body weight (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications).Ivermectin 1% lotion (1 to 3 applications) versus permethrin 5% cream (1 to 3 applications).Ivermectin systemic (1 dose) versus ivermectin systemic (2 to 3 doses).

We have reported comparisons addressing our predefined outcomes in more detail below. If there is no paragraph describing an outcome or a specific time point, it was not reported in any of the included studies.

### Oral ivermectin versus topical permethrin {#CD012994-sec3-0028}

#### Ivermectin 200 μg/kg body weight (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications) (1129 participants, 10 trials) {#CD012994-sec4-0024}

Ten studies compared ivermectin oral with permethrin 5% cream ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0015]).

##### Complete clearance {#CD012994-sec5-0008}

###### One‐week follow‐up {#CD012994-sec6-0001}

Eight studies reported the outcome 'complete clearance\' one week after treatment initiation.

Six studies including a total of 613 participants could be pooled using a random‐effects meta‐analysis model ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0015]). Heterogenerity was not significant (I² = 35%, P = 0.18). The pooled estimate shows that permethrin may be slightly more effective than ivermectin (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.54 to 0.78; [Analysis 1.1](#CD012994-fig-00101){ref-type="fig"}, [Figure 3](#CD012994-fig-0003){ref-type="fig"}). This translates to 229 fewer patients per 1000 achieving complete clearance in the ivermectin group (from 144 fewer to 301 fewer; [Table 1](#CD012994-tbl-0001){ref-type="table"}). We rated the certainty of evidence as low; see [Table 1](#CD012994-tbl-0001){ref-type="table"}.Figure 3Forest plot of comparison: 1 Ivermectin 200 μg/kg versus permethrin 5% cream, outcome: 1.1 Complete clearance ‐ week 1.

These results are in line with the results reported by [@CD012994-bbs2-0004], who stated that after one week of treatment 74.8% of participants treated with permethrin and 30.0% of participants treated with ivermectin achieved complete clearance; absolute numbers were not reported and could not be deducted.

[@CD012994-bbs2-0007] investigated 'complete improvement\' based on pruritus and lesions separately. A difference for complete improvement based on lesions alone was found in favour of permethrin (RR 0.74, 95% CI 0.56 to 0.99; 120 participants); for complete improvement based on pruritus no difference was found (RR 0.82, 95% CI 0.60 to 1.11; 120 participants).

###### Two weeks\' follow‐up {#CD012994-sec6-0002}

Six studies reported the outcome 'complete clearance\' after two weeks of treatment ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]). Of these, [@CD012994-bbs2-0004] reported results as percentages only: 99.0% of participants treated with permethrin and 63.0% of participants treated with ivermectin achieved complete clearance after two weeks. Absolute numbers could not be deducted. The combined effect estimate of the remaining five studies showed no difference between the treatment groups (RR 0.91, 95% CI 0.76 to 1.08; 459 participants; [Analysis 1.2](#CD012994-fig-00102){ref-type="fig"}, [Figure 4](#CD012994-fig-0004){ref-type="fig"}). A statistically significant heterogeneity test (I² = 61%, P = 0.04) led us to further investigate the source of heterogeneity. Risk of bias was low to high and very divergent between studies. We could not identify meaningful groups of studies based on the 'Risk of bias\' assessments that would help explain heterogeneity. In the studies by [@CD012994-bbs2-0003] and [@CD012994-bbs2-0010], uncured participants had been re‐treated after one week; absolute numbers were not provided. Visual inspection of the forest plot suggests that the trial by [@CD012994-bbs2-0013] may be one of the causes of substantial statistical heterogeneity, though we could not identify any clinical or methodological reasons. Omitting either of these studies from the meta‐analysis did not substantially change the effect estimate. Sensitivity analyses neither changed the point estimates nor whether the CI crossed the line of no effect ([Appendix 2](#CD012994-sec2-0017){ref-type="app"}). Hence, we pooled data from all five studies. We rated the certainty of the evidence as low ([Table 1](#CD012994-tbl-0001){ref-type="table"}).Figure 4Forest plot of comparison: 1 Ivermectin 200 μg/kg versus permethrin 5% cream, outcome: 1.2 Complete clearance ‐ week 2.

###### Four weeks\' follow‐up {#CD012994-sec6-0003}

Seven studies reported 'complete clearance\' after four weeks ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0005]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0015]).

A study by [@CD012994-bbs2-0012] compared one dose of ivermectin with one application of permethrin 5% cream. After four weeks of follow‐up no difference was found (RR 1.00, 95% CI 0.86 to 1.16; 80 participants). We rated the certainty of the evidence as high ([Analysis 1.3](#CD012994-fig-00103){ref-type="fig"}: subgroup 1, [Figure 5](#CD012994-fig-0005){ref-type="fig"}, and [Table 1](#CD012994-tbl-0001){ref-type="table"}).Figure 5Forest plot of comparison: 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), outcome: 1.3 Complete clearance ‐ week 4.

In five studies uncured participants were re‐treated after one week, [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0015], and/or after two weeks ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0015]). Additionally, [@CD012994-bbs2-0004] planned to switch non‐responders to permethrin 5% after three weeks. This could have affected only one participant in the ivermectin group (not clearly stated).

We observed statistically significant heterogeneity between the five trials (I² = 74%, P = 0.004), but could not identify potential reasons based on either the direction of the effect or due to a different treatment regimen. We also performed subgroup analyses, creating a subgroup excluding the two studies from sensitivity analysis. The test for subgroup differences was non‐significant (I² = 6%, P = 0.30, see [Analysis 1.4](#CD012994-fig-00104){ref-type="fig"}). Irrespective of the number of pooled studies, the combined estimates showed no differences between the groups (RR 0.92, 95% CI 0.82 to 1.03; 581 participants, 5 trials; [Analysis 1.3](#CD012994-fig-00103){ref-type="fig"}: subgroup 2, [Figure 5](#CD012994-fig-0005){ref-type="fig"}, [Appendix 2](#CD012994-sec2-0017){ref-type="app"} for sensitivity analysis). We rated the certainty of the evidence as low ([Table 1](#CD012994-tbl-0001){ref-type="table"}).

[@CD012994-bbs2-0005] and [@CD012994-bbs2-0012] treated participants with two doses of ivermectin (initial treatment and at two weeks\' follow‐up) compared to one application of permethrin 5% cream. After four weeks, no difference could be found based on the results reported by [@CD012994-bbs2-0012] (RR 0.97, 95% CI 0.83 to 1.14; 80 participants; [Analysis 1.3](#CD012994-fig-00103){ref-type="fig"}: subgroup 3, [Figure 5](#CD012994-fig-0005){ref-type="fig"}). We rated the certainty of the evidence as high ([Table 1](#CD012994-tbl-0001){ref-type="table"}).

In the trial by [@CD012994-bbs2-0005], 90.0% of participants treated with permethrin and 96.0% of participants treated with ivermectin achieved 'improvement clinically\' after four weeks (no further information provided).

##### Number of participants re‐treated {#CD012994-sec5-0009}

None of the included studies had a predefined outcome measure assessing the 'number of participants re‐treated\'. Hence, reporting differed greatly. Most studies did not report absolute numbers or proportions of participants having been re‐treated. In [Appendix 3](#CD012994-sec2-0018){ref-type="app"}, we have provided an overview of when treatment was repeated. Only two studies did not repeat their intervention ‐ neither as part of the treatment schedule nor in response to uncured participants.

##### Number of participants with at least one adverse event {#CD012994-sec5-0010}

The reporting of adverse events was poor.

###### Two weeks\' follow‐up {#CD012994-sec6-0004}

In the study by [@CD012994-bbs2-0003], none of the 55 participants experienced any adverse events. An effect estimate is not calculable; we rated the certainty of the evidence as moderate ([Analysis 1.5](#CD012994-fig-00105){ref-type="fig"} and [Table 1](#CD012994-tbl-0001){ref-type="table"}).

###### Four weeks\' follow‐up {#CD012994-sec6-0005}

Four studies including 502 participants reported data for participants experiencing at least one adverse event after four weeks ([@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0015]). We found low‐certainty evidence that ivermectin may lead to a slightly larger proportion of participants with at least one adverse event (RR 1.30, 95% CI 0.35 to 4.83; moderate heterogeneity: I² = 48%, P = 0.12; [Analysis 1.6](#CD012994-fig-00106){ref-type="fig"}, [Figure 6](#CD012994-fig-0006){ref-type="fig"}, [Table 1](#CD012994-tbl-0001){ref-type="table"}).Figure 6Forest plot of comparison: 1 Ivermectin 200 μg/kg versus permethrin 5% cream, outcome: 1.5 Number of participants with ≥ 1 adverse event ‐ week 4.

[@CD012994-bbs2-0005] and [@CD012994-bbs2-0010] reported zero events per group, however the number of participants assessed at week four is unclear.

In the trial by [@CD012994-bbs2-0013], participants were evaluated after eight weeks. In the ivermectin group, three out of 40 participants experienced at least one adverse event, while none of the 45 analysed participants in the permethrin group experienced an event.

##### Number of participants withdrawn from study due to adverse event {#CD012994-sec5-0011}

###### Four weeks\' follow‐up {#CD012994-sec6-0006}

In three studies with 305 randomized participants ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0015]), no withdrawals due to adverse events occurred ([Analysis 1.7](#CD012994-fig-00107){ref-type="fig"}). We rated the certainty of the evidence as moderate ([Table 1](#CD012994-tbl-0001){ref-type="table"}).

#### Ivermectin 200 μg/kg body weight (1 to 2 doses) versus permethrin 5% lotion (1 or 5 applications) (227 participants, 2 trials) {#CD012994-sec4-0025}

Two studies compared oral ivermectin 200 µg/kg body weight with permethrin 5% lotion ([@CD012994-bbs2-0011]; [@CD012994-bbs2-0001]). In the study by [@CD012994-bbs2-0001], children randomized to the permethrin group below the age of 10 were treated with permethrin 2.5% lotion.

##### Complete clearance {#CD012994-sec5-0012}

###### One and two weeks\' follow‐up {#CD012994-sec6-0007}

In [@CD012994-bbs2-0011], participants were treated with either a single dose of ivermectin or a single application of permethrin 5% lotion. Complete clearance was defined as no itching, cutaneous lesions/burrows, and negative microscopy. There was no difference between study groups (week one: RR 0.93, 95% CI 0.74 to 1.17; [Analysis 2.1](#CD012994-fig-00201){ref-type="fig"}: subgroup 1; week two: RR 1.00, 95% CI 0.78 to 1.29; [Analysis 2.2](#CD012994-fig-00202){ref-type="fig"}: subgroup 1; 120 participants each). We rated the certainty of the evidence as moderate and low, respectively ([Table 2](#CD012994-tbl-0002){ref-type="table"}).

In the study by [@CD012994-bbs2-0001], 107 participants were treated either with a single dose of ivermectin or with permethrin 5% lotion on five consecutive nights. Complete clearance was defined as negative parasitological examination of the participant with complete absence of new lesions. After one week, permethrin may have lead to slightly more participants with complete clearance (RR 0.70, 95% CI 0.47 to 1.03; [Analysis 2.1](#CD012994-fig-00201){ref-type="fig"}: subgroup 2). After two weeks, no difference was found (RR 0.97, 95% CI 0.81 to 1.17; [Analysis 2.2](#CD012994-fig-00202){ref-type="fig"}: subgroup 2). We rated the certainty of the evidence as low and moderate, respectively ([Table 2](#CD012994-tbl-0002){ref-type="table"}).

##### Number of participants re‐treated {#CD012994-sec5-0013}

The two studies comparing ivermectin 200 µg/kg with permethrin 5% lotion had different treatment schedules, as shown in [Appendix 3](#CD012994-sec2-0018){ref-type="app"}.

##### Number of participants with at least one adverse event {#CD012994-sec5-0014}

###### Two weeks\' follow‐up {#CD012994-sec6-0008}

[@CD012994-bbs2-0001] found no difference between groups in number of participants with at least one adverse event (RR 5.00, 95% CI 0.25 to 101.58; 100 participants; [Analysis 2.3](#CD012994-fig-00203){ref-type="fig"}). We rated the certainty of the evidence as very low ([Table 2](#CD012994-tbl-0002){ref-type="table"}).

##### Number of participants withdrawn from study due to adverse event {#CD012994-sec5-0015}

###### Two weeks\' follow‐up {#CD012994-sec6-0009}

[@CD012994-bbs2-0011] reported that no participants withdrew from the study due to adverse events in either group (120 participants; [Analysis 2.4](#CD012994-fig-00204){ref-type="fig"}). We rated the certainty of the evidence as moderate ([Table 2](#CD012994-tbl-0002){ref-type="table"}).

#### Ivermectin 200 μg/kg body weight (1 dose) versus permethrin 5% (1 application) (100 participants, 1 trial) {#CD012994-sec4-0026}

We identified only one study, [@CD012994-bbs2-0014], whose data were published as an abstract only.

##### Complete clearance {#CD012994-sec5-0016}

[@CD012994-bbs2-0014] investigated ivermectin 200 µg/kg body weight and permethrin 5% of unknown ointment base. Participants were evaluated one and two weeks\' post‐treatment initiation. The authors state that \"Permethrin had significantly better cure rate than ivermectin\" ([@CD012994-bbs2-0014]). The number of randomized participants per group, the definition of 'cure\', and the time point of evaluation were not reported.

##### Number of participants re‐treated {#CD012994-sec5-0017}

[@CD012994-bbs2-0014] stated that participants with no sign of cure received the same treatments again after one week ([Appendix 3](#CD012994-sec2-0018){ref-type="app"}).

### Oral ivermectin versus topical ivermectin {#CD012994-sec3-0029}

#### Ivermectin 200 μg/kg body weight (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications) (272 participants, 2 trials) {#CD012994-sec4-0027}

Two studies compared ivermectin oral with ivermectin 1% lotion, [@CD012994-bbs2-0004], or 1% solution, [@CD012994-bbs2-0002].

##### Complete clearance {#CD012994-sec5-0018}

###### One‐week follow‐up {#CD012994-sec6-0010}

In [@CD012994-bbs2-0002], there was no difference between study groups after one week of follow‐up (RR 0.84, 95% CI 0.65 to 1.08; 62 participants; [Analysis 3.1](#CD012994-fig-00301){ref-type="fig"}). We rated the certainty of evidence as low ([Table 3](#CD012994-tbl-0003){ref-type="table"}).

In [@CD012994-bbs2-0004], 30.0% of participants treated with ivermectin 200 μg/kg body weight and 69.3% of participants treated with ivermectin 1% lotion achieved 'complete clearance\' after one week. Reported data were insufficient for calculating an effect estimate.

###### Two weeks\' follow‐up {#CD012994-sec6-0011}

In [@CD012994-bbs2-0002], there was no difference between study groups after two weeks of follow‐up (RR 1.00, 95% CI 0.94 to 1.06; 62 participants; [Analysis 3.2](#CD012994-fig-00302){ref-type="fig"}). We rated the certainty of evidence as moderate ([Table 3](#CD012994-tbl-0003){ref-type="table"}).

In [@CD012994-bbs2-0004], 63.0% of participants treated with ivermectin 200 μg/kg body weight achieved 'complete clearance\', whereas 100.0% of participants treated with ivermectin 1% lotion were cleared after two weeks of follow‐up. Absolute numbers of participants were not reported ([@CD012994-bbs2-0004]).

###### Four weeks\' follow‐up {#CD012994-sec6-0012}

Pooled data from [@CD012994-bbs2-0004] and [@CD012994-bbs2-0002] revealed no difference between study groups for 'complete clearance\' after four weeks of follow‐up (RR 0.99, 95% CI 0.95 to 1.03; 272 participants; [Analysis 3.3](#CD012994-fig-00303){ref-type="fig"}). We rated the certainty of evidence as moderate ([Table 3](#CD012994-tbl-0003){ref-type="table"}).

##### Number of participants re‐treated {#CD012994-sec5-0019}

[@CD012994-bbs2-0002] re‐treated non‐responders after one week. Four out of 32 participants in the topical ivermectin group and eight out of 30 participants in the systemic ivermectin group were re‐treated. [@CD012994-bbs2-0004] re‐treated those participants who were not cured at week one and week two. Non‐responders at week three switched to permethrin. Absolute numbers were not reported ([Appendix 3](#CD012994-sec2-0018){ref-type="app"}).

##### Number of participants with at least one adverse event {#CD012994-sec5-0020}

###### Four weeks\' follow‐up {#CD012994-sec6-0013}

We found no difference between groups for the number of participants with at least one adverse event within four weeks of follow‐up (RR 5.05, 95% CI 0.25 to 103.87; 201 participants; [Analysis 3.4](#CD012994-fig-00304){ref-type="fig"}). We rated the certainty of the evidence as very low ([Table 3](#CD012994-tbl-0003){ref-type="table"}).

##### Number of participants withdrawn from study due to adverse event {#CD012994-sec5-0021}

###### Four weeks\' follow‐up {#CD012994-sec6-0014}

None of the 62 randomized participants in [@CD012994-bbs2-0002] withdrew due to an adverse event ([Analysis 3.5](#CD012994-fig-00305){ref-type="fig"}). We rated the certainty of evidence as moderate ([Table 3](#CD012994-tbl-0003){ref-type="table"}).

### Topical ivermectin versus topical permethrin {#CD012994-sec3-0030}

#### Ivermectin 1% lotion (1 to 3 applications) versus permethrin 5% cream (1 to 3 applications) (210 participants, 1 trial) {#CD012994-sec4-0028}

##### Complete clearance {#CD012994-sec5-0022}

###### One‐week follow‐up {#CD012994-sec6-0015}

In [@CD012994-bbs2-0004], 69.3% of participants treated with ivermectin 1% lotion and 74.8% of participants treated with permethrin 5% cream achieved 'complete clearance\' after one week. Reported data were insufficient to calculate an effect estimate.

###### Two weeks\' follow‐up {#CD012994-sec6-0016}

After two weeks of follow‐up, 100.0% of the participants treated with ivermectin 1% lotion achieved 'complete clearance\' and 99.0% of the participants treated with permethrin 5% cream were cleared. Absolute numbers of participants were not reported.

###### Four weeks\' follow‐up {#CD012994-sec6-0017}

Data reported by [@CD012994-bbs2-0004] showed no difference between the study groups after four weeks of follow‐up for complete clearance (RR 1.02, 95% CI 0.96 to 1.08; 210 participants; [Analysis 4.1](#CD012994-fig-00401){ref-type="fig"}). We rated the certainty of the evidence as moderate ([Table 4](#CD012994-tbl-0004){ref-type="table"}).

##### Number of participants re‐treated {#CD012994-sec5-0023}

[@CD012994-bbs2-0004] re‐treated those participants who were not cured at week one and week two. Non‐responders at week three were switched to permethrin. Absolute numbers were not reported ([Appendix 3](#CD012994-sec2-0018){ref-type="app"}).

##### Number of participants with at least one adverse event {#CD012994-sec5-0024}

###### Four weeks\' follow‐up {#CD012994-sec6-0018}

We could find no difference between the groups for the number of participants with at least one adverse event within four weeks of follow‐up (RR 0.33, 95% CI 0.01 to 7.93; 200 participants; [Analysis 4.2](#CD012994-fig-00402){ref-type="fig"}). We rated the certainty of the evidence as very low ([Table 4](#CD012994-tbl-0004){ref-type="table"}).

### Oral ivermectin versus oral ivermectin in different doses {#CD012994-sec3-0031}

#### Ivermectin 200 μg/kg body weight (1 dose) versus ivermectin 200 μg/kg body weight (2 doses) (80 participants, 1 trial) {#CD012994-sec4-0029}

##### Complete clearance {#CD012994-sec5-0025}

###### Four weeks\' follow‐up {#CD012994-sec6-0019}

[@CD012994-bbs2-0012], which included 80 participants, found no difference between one and two doses of oral ivermectin for 'complete clearance\' after four weeks of follow‐up (RR 0.97, 95% CI 0.83 to 1.14; [Analysis 5.1](#CD012994-fig-00501){ref-type="fig"}; [Table 5](#CD012994-tbl-0005){ref-type="table"}). We rated the certainty of the evidence as high.

##### Number of participants re‐treated {#CD012994-sec5-0026}

As planned by [@CD012994-bbs2-0012], none of the participants were re‐treated, except as defined in the study protocol ([Appendix 3](#CD012994-sec2-0018){ref-type="app"}).

#### Ivermectin 250 μg/kg body weight (1 dose) versus ivermectin 250 μg/kg body weight (3 doses) (273 participants, 1 trial) {#CD012994-sec4-0030}

##### Complete clearance {#CD012994-sec5-0027}

[@CD012994-bbs2-0006], which involved 273 participants, investigated a single dose ivermectin at day 1 versus three doses of ivermectin on day 1, 3, and 10. Absolute numbers were not reported. All participants were cured within 45 days of follow‐up. 'Cure\' was defined as considerable improvement of dermatosis, no pruritus, and no new lesions. The exact time point of evaluation is unclear.

##### Number of participants re‐treated {#CD012994-sec5-0028}

[@CD012994-bbs2-0006] did not report on additional re‐treatment of participants, except as stipulated in the study protocol ([Appendix 3](#CD012994-sec2-0018){ref-type="app"}).

##### Number of participants with at least one adverse event {#CD012994-sec5-0029}

The authors reported that there were no adverse drug reactions ([@CD012994-bbs2-0006]).

Discussion {#CD012994-sec1-0006}
==========

Summary of main results {#CD012994-sec2-0011}
-----------------------

Fifteen trials, comprising 1896 participants treated with ivermectin or permethrin, met our inclusion criteria. Nearly all studies were conducted in South Asia or North Africa, where many people live in poor, overcrowded conditions. We have presented our findings in five 'Summary of findings\' tables ([Table 1](#CD012994-tbl-0001){ref-type="table"}; [Table 2](#CD012994-tbl-0002){ref-type="table"}; [Table 3](#CD012994-tbl-0003){ref-type="table"}; [Table 4](#CD012994-tbl-0004){ref-type="table"}; [Table 5](#CD012994-tbl-0005){ref-type="table"}).

The differences in the efficacy results, the number of participants with adverse events, and the number of participants withdrawn due to adverse events were small.

### Efficacy {#CD012994-sec3-0032}

We analysed 13 studies comprising 1456 participants evaluating systemic ivermectin versus permethrin. Oral ivermectin at a standard dose of 200 μg/kg may lead to slightly lower rates of complete clearance after one week compared to permethrin 5% cream (extrapolated cure rates based on anticipated absolute effects: permethrin 65%, ivermectin 43%; RR 0.65, 95% CI 0.54 to 0.78; 613 participants, 6 studies; low‐certainty evidence), but may lead to little or no difference in rates of complete clearance by week two (extrapolated cure rates based on anticipated absolute effects: permethrin 74%, ivermectin 68%; RR 0.91, 95% CI 0.76 to 1.08; 459 participants, 5 studies; low‐certainty evidence).

In two out of 13 studies ([@CD012994-bbs2-0011]; [@CD012994-bbs2-0007]), the re‐treatment of participants was not planned. Uncured participants in seven studies were re‐treated ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0014]; [@CD012994-bbs2-0015]); however, only two of these studies reported numbers ([@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]), finding that more participants in the systemic ivermectin groups were re‐treated than in the permethrin groups. It is unclear whether the re‐treatment of participants in these seven studies who did not show complete clearance had been planned or not. Additionally, three studies reported that all participants in the ivermectin group were re‐treated after one or two weeks, irrespective of treatment response ([@CD012994-bbs2-0005]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0001]). [@CD012994-bbs2-0008] repeated treatment in all participants.

Study investigators may have chosen to repeat the treatment because ivermectin, unlike permethrin, only affects the mite and not the egg. After one dose, considering the life cycle of the scabies mite (10 to 17 days), a second treatment with ivermectin might be necessary. Alternatively, ivermectin might have a slower onset of action. Studies that included some form of re‐treatment (see [Appendix 3](#CD012994-sec2-0018){ref-type="app"}) comparing permethrin cream and oral ivermectin may lead to little or no difference in rates of complete clearance after four weeks (extrapolated cure rates based on anticipated absolute effects: 1 to 3 applications of permethrin 93%, 1 to 3 doses of ivermectin 86%; RR 0.92, 95% CI 0.82 to 1.03; 581 participants, 5 studies; low‐certainty evidence). Considering the cure rates after one or two weeks of treatment, we assume that the number of participants needing re‐treatment was low to medium. However, suboptimal reporting precludes further judgement.

Likewise, after four weeks ivermectin lotion probably leads to little or no difference in rates of complete clearance when compared to permethrin cream (extrapolated cure rates based on anticipated absolute effects: permethrin cream 94%, ivermectin lotion 96%; RR 1.02, 95% CI 0.96 to 1.08; 210 participants, 1 study; moderate‐certainty evidence, up to two re‐treatments of non‐responders, numbers unclear; [@CD012994-bbs2-0004])*,* which may support the above mentioned assumptions. Furthermore, there is probably little or no difference in rates of complete clearance between oral ivermectin at standard dose and topical ivermectin 1% lotion four weeks after initiation of treatment (extrapolated cure rates based on anticipated absolute effects: oral ivermectin 97%, ivermectin lotion 96%; RR 0.99, 95% CI 0.95 to 1.03; 272 participants, 2 studies; moderate‐certainty evidence; up to two re‐treatments of non‐responders, numbers unclear; [@CD012994-bbs2-0004] and [@CD012994-bbs2-0002]). The dose comparison study showed that one dose of systemic ivermectin led to little or no difference in rates of complete clearance compared to two doses of systemic ivermectin (extrapolated cure rates based on anticipated absolute effects: 2 doses 90%, 1 dose 87%; RR 0.97, 95% CI 0.83 to 1.14; 80 participants, 1 study; high‐certainty evidence). This finding weakens our assumptions as described above. While this study had one of the smallest sample sizes, the methodological conduct and reporting appeared best, giving it more weight.

We did not identify any differences in efficacy between permethrin and ivermectin other than after one week of treatment. Our findings do not allow for a conclusion about the onset of action in topical treatments compared to systemic treatments, as this was not directly assessed.

### Safety {#CD012994-sec3-0033}

Generally, systemic and topical drugs can lead to different types of events, endangering blinding. Only two of the studies included in this review were blinded. While the reporting of adverse events in the included studies was suboptimal, it appears that very few adverse events occurred. Two weeks after treatment initiation, there is probably little or no difference in the proportion of participants treated with systemic ivermectin or permethrin cream who experienced at least one adverse event (55 participants, 1 study; moderate‐certainty evidence). After four weeks, ivermectin may lead to a slightly larger proportion of participants with at least one adverse event (extrapolated rates: permethrin 4%, ivermectin 5%*;* RR 1.30, 95% CI 0.35 to 4.83; 502 participants, 4 studies; low‐certainty evidence). In scabies treatment, medications are sometimes given more than once. However, even the studies with repeated applications did not report more adverse events. To add, no withdrawals due to adverse events occurred in either the systemic ivermectin or the permethrin group *(*moderate‐certainty evidence). In most studies in which participants were treated only once, a possible explanation for zero withdrawals could be that participants who experienced adverse events after their first (and only) treatment remained in study because they had already had their treatment.

The studies analysed for this review reported severe itching, secondary bacterial infections, headache, and nausea in people treated with systemic ivermectin ([@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]).

Regarding permethrin, the analysed studies in this review rarely stated the frequency of adverse events and did not designate their types. Only erythema, burning, and pruritus were reported during permethrin treatment ([@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]).

Two analysed studies evaluating systemic versus topical ivermectin reported that adverse events were rare and of mild intensity and comparable in both study groups ([@CD012994-bbs2-0004]; [@CD012994-bbs2-0002]). It is uncertain whether there was any difference in the proportion of participants with at least one adverse event (very low‐certainty evidence). No withdrawals due to adverse events occurred, which supports these findings (62 participants, 1 study; moderate‐certainty evidence).

Furthermore, it is uncertain whether topical ivermectin or permethrin differ in the number of participants with at least one adverse event (very low‐certainty evidence). We found no studies comparing systemic ivermectin in different doses that assessed our predefined safety outcomes.

Overall completeness and applicability of evidence {#CD012994-sec2-0012}
--------------------------------------------------

Applicability to Western countries and external validity ‐ apart from the obvious differences between RCT conditions and real‐world conditions ‐ is limited due to studies being conducted in regions with a high prevalence of scabies. Most included trials were conducted in lower‐middle‐income countries (India, Pakistan, and Egypt). Only one study was undertaken in Mexico in the beginning of the 1990s (middle‐income country). All studies were conducted in resource‐poor countries.

We identified only single‐centre studies that included predominately small numbers of participants per study group. The included studies were inconsistent in their descriptions, definitions, and assessments of cure as well as in the frequencies of treatment application. Pooling data or comparing data across participant groups was therefore difficult or inappropriate.

Although permethrin is an ovicidal medication, in some of the included studies it was applied twice. Conversely, in some studies evaluating ivermectin, a non‐ovicidal medication, the drug was administered only once. None of these studies explained the scientific rationale behind these a priori defined dosages, although permethrin is often administered twice due to compliance and re‐infestation issues (see [How the intervention might work](#CD012994-sec2-0003){ref-type="sec"}).

Quality of the evidence {#CD012994-sec2-0013}
-----------------------

We assessed the certainty of the evidence according to the GRADE approach and presented it in five 'Summary of findings\' tables ([Table 1](#CD012994-tbl-0001){ref-type="table"}; [Table 2](#CD012994-tbl-0002){ref-type="table"}; [Table 3](#CD012994-tbl-0003){ref-type="table"}; [Table 4](#CD012994-tbl-0004){ref-type="table"}; [Table 5](#CD012994-tbl-0005){ref-type="table"}).

The main reasons for downgrading the certainty of the evidence were the quality of the trials and imprecision in the results. In general, the methodological quality of the trials included in this review was moderate. We assessed most of the studies as having a high risk of performance and detection bias. We rated attrition bias as high in nearly half of the included studies. We downgraded certainty for imprecision, mainly because minimal clinically important difference thresholds were crossed by the CIs or the CIs were wide.

Substantial heterogeneity between trials became apparent in two meta‐analyses ([Analysis 1.2](#CD012994-fig-00102){ref-type="fig"} and [Analysis 1.3](#CD012994-fig-00103){ref-type="fig"}). This could be explained by variations in the numbers of re‐treated participants, which were not stated in most studies. However, the sensitivity analyses ([Appendix 2](#CD012994-sec2-0017){ref-type="app"}) did not help to further explain this, and it restricts our confidence in the results.

Potential biases in the review process {#CD012994-sec2-0014}
--------------------------------------

While we considered publication bias to be undetected, we cannot rule it out. Nearly all included studies were conducted in resource‐poor nations. It is unknown if studies were conducted but not published or not identified through our comprehensive searches. One‐fifth of the included studies were not identified via the systematic searches of academic, trial, and grey literature repositories, but through web searches (n = 1) and through screening of reference lists (n = 2). We did not consult experts.

It should be noted that it is not clear what impact the three excluded studies ‐ whose validity is questionable (see [Excluded studies](#CD012994-bbs1-0002){ref-type="ref-list"}) ‐ would have on the overall findings of this review.

Despite clear inclusion criteria, individual interpretation or human mistakes may lead to different results in data extraction. We attempted to preclude this potential bias by ensuring that two review authors read all full texts and extracted data independently. All disagreements were discussed fully.

In some cases, we were unable to extract all relevant data because reporting was poor or incomplete (for example, absolute numbers of evaluated participants) in publications. We contacted study authors in an effort to overcome these issues. However, most authors did not respond to our inquiries.

In order to avoid the issue of multiplicity, we chose only one primary outcome at three time points and only reported effects measures/CIs instead of testing for significance.

Agreements and disagreements with other studies or reviews {#CD012994-sec2-0015}
----------------------------------------------------------

Our results comparing permethrin and systemic ivermectin are similar to our recently published comprehensive systematic review considering several scabies treatments ([@CD012994-bbs2-0044]). [@CD012994-bbs2-0044] concluded that there is no difference between a single dose of permethrin 5% and systemic ivermectin.

Of interest is also a larger study by [@CD012994-bbs2-0079], who randomized three island communities in Fiji to either permethrin for only affected patients and their contacts (standard treatment) or permethrin for all island inhabitants or ivermectin for all inhabitants. After 12 months, systemic ivermectin was found to be superior to topical permethrin ([@CD012994-bbs2-0044]). [@CD012994-bbs2-0079] reported that the prevalence declined by 49% in the standard treatment group, 62% in the permethrin group, and 94% in the ivermectin group after one year.

Authors\' conclusions {#CD012994-sec1-0007}
=====================

Topical permethrin, topical ivermectin, and systemic ivermectin all lead to high clearance rates in the treatment of scabies. Highly relevant differences could not be seen in the identified trials.The choice of one of these three treatments can be guided by considerations of practicability, availability, drug licensing, and costs depending on the individual setting.Permethrin and ivermectin as topical treatments are appropriate for patients in which the correct application to the whole body can be properly ensured. Systemic ivermectin may be given preference if proper application cannot be ensured or if very large groups of patients need to be treated and proper instructions and topical application is not feasible.Further limitations apply with regard to the age of the patients and in case of pregnancy and breastfeeding. Systemic ivermectin is not indicated during pregnancy or for children weighing less than 15 kg.The need for a single versus a repeated application cannot be properly answered based on the identified trial results. For most patients, a single treatment is likely sufficient. The treating physician may take into account the extent of the disease, the number of contact persons affected, the likeliness of correct application, the immune status, and the clinical response during follow‐up as an indicator for the need of a second application.Due to suboptimal study conduct, design, or reporting and, for example, the small sample sizes, the certainty of the level of evidence is restricted, which limits our confidence in the effect estimates. Randomized controlled trials of good methodological quality complying with current reporting standards (for example, CONSORT) are necessary to reduce risk of bias and and improve the evidence base.The question of repeated treatment, that is when and how often, cannot be answered conclusively. Further studies with clear and strict treatment regimens are needed.Adverse events were rare and poorly reported in the included studies. Studies with a larger sample size and better documentation and classification of adverse events could overcome this issue.The proportion of participants withdrawn due to non‐response or adverse events is poorly reported. It is unlikely that new studies from middle‐income countries investigating systemic ivermectin versus topical permethrin will change the results ([@CD012994-bbs2-0072]).Discussions on resistance to scabious treatments have emerged, however such cases have been regionally limited, and the overall evidence is scarce. Studies focusing on a possible development of resistance may become necessary in the future.Public health questions like mass drug interventions for prevention and treatment of scabies were not addressed in this review but could be part of further research and other reviews ([@CD012994-bbs2-0079]).

We thank Mark Strong and Paul Johnstone, authors of the Cochrane Review 'Interventions for treating scabies\' ([@CD012994-bbs2-0088]), which served as a basis for this review. We are heavily indebted to both of them for passing the topic on to us and for preparing the '[Background](#CD012994-sec1-0002){ref-type="sec"}\' section. We are also grateful to Anne‐Marie Stephani and Paul Garner of the editorial office of the Cochrane Infectious Diseases Group (CIDG) for their administrative support. We thank Vittoria Lutje for preparing and running the searches in online databases and trial registries.

The CIDG editorial base is funded by the UK Department for International Development (DFID) for the benefit of low‐ and middle‐income countries (Grant: 5242).

We are also grateful to Ricardo Niklas Werner for the translation, data extraction, and evaluation of the study published in Spanish.

**Search setCIDG SR^a^/ EconLit/ ERICCENTRALMEDLINE/Embase^b^LILACS^b^IndMED**1scabiesscabies ti, abscabies ti, abscabiesscabies2---\"scabies\" \[MeSH\]\"scabies\" \[MeSH/Emtree\]permethrinsarcoptes scabiei3---\"sarcoptes scabiei\" \[MeSH\]\"sarcoptes scabiei\" \[MeSH/Emtree\]ivermectin1 or 24---1 or 2 or 31 or 2 or 32 or 3---5---permethrin ti, abpermethrin ti, ab1 and 4---6---\"permethrin\" \[MeSH\]\"permethrin\" \[MeSH/Emtree\]------7---\"pyrethrins\" \[MeSH\]\"pyrethrins\" \[MeSH\]------8---ivermectin ti, ab\"pyrethroid\" \[Emtree\]------9---\"ivermectin\" \[MeSH\]ivermectin ti, ab------10---5 or 6 or 7 or 8 or 9\"ivermectin\" \[MeSH/Emtree\]------11---4 and 105 or 6 or 7 or 8 or 9 or 10------12------4 and 11------

^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration ([@CD012994-bbs2-0067]).

**ComparisonSubgroupOutcomeSensitivity analysisMeta‐analysis**Ivermectin 200 μg/kg versus permethrin 5% cream---Complete clearance ‐ week 2Without [@CD012994-bbs2-0013] (significant effect estimate):\
RR 0.96, 95% CI 0.88 to 1.06 (I² statistic = 0%)\
Without [@CD012994-bbs2-0003]; [@CD012994-bbs2-0010] (some participants were re‐treated after 1 week):\
RR 0.81, 95% CI 0.56 to 1.19 (I² statistic = 71%)RR 0.91, 95% CI 0.76 to 1.08 (I² statistic = 61%)IVER 1 to 3 doses versus PER 1 to 3 dosesComplete clearance ‐ week 4Without [@CD012994-bbs2-0013] (significant effect estimate):\
RR 0.97, 95% CI 0.91 to 1.05 (I² statistic = 31%)\
Without [@CD012994-bbs2-0013]; [@CD012994-bbs2-0009] (non‐responders re‐treated after 2 weeks):\
RR 0.98, 95% CI 0.91 to 1.06 (I² statistic = 36%)RR 0.92, 95% CI 0.82 to 1.03 (I² statistic = 74%)

**Abbreviations:** CI: confidence interval; IVER: ivermectin; PER: permethrin; RR: risk ratio.

**StudyInitial treatmentFollow‐up week 1Follow‐up week 2Follow‐up week 3Follow‐up week 4Studies that treated participants once**[@CD012994-bbs2-0007]1 x IVER 200 µg/kg‐‐‐‐1 x PER 5%‐‐‐‐[@CD012994-bbs2-0011]1 x IVER 200 µg/kg‐‐‐‐1 x PER 5%‐‐‐‐**Studies that treated participants once and re‐treated only non‐responders**[@CD012994-bbs2-0002]1 x IVER 1%Yes, 4/32 participants‐‐‐1 x IVER 200 µg/kgYes, 8/30 participants‐‐‐[@CD012994-bbs2-0003]1 x IVER 200 µg/kgYes, 44.44% of participants‐‐‐1 x PER 5%Yes, 17.86% of participants‐‐‐[@CD012994-bbs2-0004]1 x IVER 200 µg/kgYes, n unclearYes, n unclearSwitch over to PER 5%‐1 x IVER 1%Yes, n unclearYes, n unclearSwitch over to PER 5%‐1 x PER 5%Yes, n unclearYes, n unclearYes, n unclear‐[@CD012994-bbs2-0009]1 x IVER 200 µg/kg‐Yes, n unclear‐‐1 x PER 5%‐Yes, n unclear‐‐[@CD012994-bbs2-0010]1 x IVER 200 µg/kgYes, n unclear‐‐‐1 x PER 5%Yes, n unclear‐‐‐[@CD012994-bbs2-0013]1 x IVER 200 µg/kg‐Yes, 12 participants‐Cross‐over if treatment failure1 x PER 5%‐Yes, 1 participant‐Cross‐over if treatment failure[@CD012994-bbs2-0014]1 x IVER 200 µg/kgYes, n unclear‐‐‐1 x PER 5%Yes, n unclear‐‐‐[@CD012994-bbs2-0015]1 x IVER 200 µg/kgYes, n unclear‐‐‐1 x PER 5%Yes, n unclear‐‐‐**Studies that treated all participants with more than 1 dose**[@CD012994-bbs2-0001]1 x IVER 200 µg/kg1 x IVER 200 µg/kgYes, time and n unclearPER 5% for 5 consecutive nights‐[@CD012994-bbs2-0005]1 x IVER 200 µg/kg‐1 x IVER 200 µg/kg‐‐1 x PER 5%‐‐‐‐[@CD012994-bbs2-0006]1 x IVER 250 µg/kg‐‐‐‐1 x IVER 250 µg/kgDay 3: 1 x IVER 250 µg/kgDay 10: 1 x IVER 250 µg/kg‐‐[@CD012994-bbs2-0008]1 x IVER 200 µg/kg1 x IVER 200 µg/kg‐‐‐1 x PER 5%1 x PER 5%‐‐‐[@CD012994-bbs2-0012]1 x IVER 200 µg/kg‐‐‐‐1 x IVER 200 µg/kg‐Day 15: 1 x IVER 200 µg/kg‐‐1 x PER 5%‐‐‐‐

**Abbreviations:** IVER: ivermectin; PER: permethrin.

**StudyName of outcomeDefinition and evaluation**[@CD012994-bbs2-0001]Complete cureNegative parasitological examination with complete absence of new lesionsresidual and all new lesions were scraped for detection of mitesif only one mite was detected, this was considered as treatment failure[@CD012994-bbs2-0002]CureClinical assessment by 1 researcher4‐point scale for lesion count: 0 = no skin lesions; 1 = ≤ 10 lesions; 2 = 11 to 49 lesions; 3 ≥ 50 lesions)4‐point scale for pruritus: 0 = no pruritus; 1 = mild pruritus; 2 = moderate pruritus; 3 = marked prurituscure = 0laboratory diagnosis: demonstration of mites and/or mite products (eggs, larva, or faecal pellets) in scrapings from skin lesions (burrows or scabetic papules from classical sites: finger webs, flexural aspect of wrist, or penile shaft) using light microscopy after incubation in 15% potassium hydroxide[@CD012994-bbs2-0003]CureNo new lesions papules, vesicles, and classical burrowsexamined by dermatologist and principal investigator to standardize clinical evaluation[@CD012994-bbs2-0004]Clinical cure of scabietic lesionsNo definition[@CD012994-bbs2-0005]Improvement clinicallyNo definition[@CD012994-bbs2-0006]CureConsiderable improvement of dermatosis, no pruritus, no new lesions[@CD012994-bbs2-0007]Complete improvementBased on severity of pruritus or lesionslesion count: \< 10: mild, 11 to 49: moderate, \> 50: severepruritus on 10‐centimetre visual analogue scale: 0 ‐ no pruritus, 1 to 3 ‐ mild, 4 to 6 ‐ moderate, 7 to 10 ‐ severecomplete improvement not defined[@CD012994-bbs2-0008]Complete clinical cureReduction in clinical grading score up to grade 0 or 1 and reduction in itching grading score up to grade 0, 1, or 2; \"moderate or good improvement\"clinical grading score: 0 = free of lesions (no lesions), 1 = 10 or fewer lesions (mild), 2 = 11 to 49 lesions (moderate), 3 = 50 or more lesions (severe)itching grading score: participant was asked for reduction in pruritus, grading was done on given scale by the observer: 0 = 0% (no pruritus), 1 = 1% to 25% (mild pruritus), 2 = 26% to 50% (moderate pruritus), 3 = 51% to 75% (severe pruritus), 4 = 76% to 100% (very severe pruritus)[@CD012994-bbs2-0009]Cure of diseaseNo lesions[@CD012994-bbs2-0010]CureAbsence of clinical lesions and no new lesions like papules, vesicles, and classical burrows suggestive of live parasite[@CD012994-bbs2-0011]CureNo itching, cutaneous lesions/burrows, and negative microscopy[@CD012994-bbs2-0012]Complete clinical cureReduction in both the number of lesions and the grade of pruritus by more than or equal to 50% (that is, moderate and good improvement) and negative microscopy[@CD012994-bbs2-0013]Complete clearanceGood improvement[@CD012994-bbs2-0014]Cure rateNo definition[@CD012994-bbs2-0015]CureNo new clinical lesions and improvement in pruritus, no new lesions like papules, vesicles, and classical burrows suggestive of live parasite seen

Comparison 1Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Complete clearance ‐ week 1](#CD012994-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), Outcome 1 Complete clearance ‐ week 1.6613Risk Ratio (M‐H, Random, 95% CI)0.65 \[0.54, 0.78\][2 Complete clearance ‐ week 2](#CD012994-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), Outcome 2 Complete clearance ‐ week 2.5459Risk Ratio (M‐H, Random, 95% CI)0.91 \[0.76, 1.08\][3 Complete clearance ‐ week 4](#CD012994-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), Outcome 3 Complete clearance ‐ week 4.6Risk Ratio (M‐H, Random, 95% CI)Subtotals only3.1 IVER 1 dose versus PER 1 application180Risk Ratio (M‐H, Random, 95% CI)1.0 \[0.86, 1.16\]3.2 IVER 1 to 3 doses versus PER 1 to 3 applications5581Risk Ratio (M‐H, Random, 95% CI)0.92 \[0.82, 1.03\]3.3 IVER 2 doses versus PER 1 application180Risk Ratio (M‐H, Random, 95% CI)0.97 \[0.83, 1.14\][4 Subgroup analysis for 1.3.2 ‐ complete clearance ‐ week 4](#CD012994-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), Outcome 4 Subgroup analysis for 1.3.2 ‐ complete clearance ‐ week 4.5Risk Ratio (M‐H, Random, 95% CI)Subtotals only4.1 IVER 1 to 3 doses versus PER 1 to 3 applications ‐ 5 studies5581Risk Ratio (M‐H, Random, 95% CI)0.92 \[0.82, 1.03\]4.2 IVER 1 to 3 doses versus PER 1 to 3 applications ‐ 3 studies3410Risk Ratio (M‐H, Random, 95% CI)0.98 \[0.91, 1.06\][5 Number of participants with ≥ 1 adverse event ‐ week 2](#CD012994-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), Outcome 5 Number of participants with ≥ 1 adverse event ‐ week 2.155Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\][6 Number of participants with ≥ 1 adverse event ‐ week 4](#CD012994-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), Outcome 6 Number of participants with ≥ 1 adverse event ‐ week 4.4502Risk Ratio (M‐H, Random, 95% CI)1.30 \[0.35, 4.83\][7 Withdrawal due to adverse event ‐ week 4](#CD012994-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Ivermectin 200 μg/kg (1 to 3 doses) versus permethrin 5% cream (1 to 3 applications), Outcome 7 Withdrawal due to adverse event ‐ week 4.3305Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\]

Comparison 2Ivermectin 200 μg/kg (1 to 2 doses) versus permethrin 5% lotion (1 to 5 applications)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Complete clearance ‐ week 1](#CD012994-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Ivermectin 200 μg/kg (1 to 2 doses) versus permethrin 5% lotion (1 to 5 applications), Outcome 1 Complete clearance ‐ week 1.2Risk Ratio (M‐H, Random, 95% CI)Subtotals only1.1 IVER 1 dose versus PER 1 application1120Risk Ratio (M‐H, Random, 95% CI)0.93 \[0.74, 1.17\]1.2 IVER 1 dose versus PER on 5 consecutive nights1107Risk Ratio (M‐H, Random, 95% CI)0.70 \[0.47, 1.03\][2 Complete clearance ‐ week 2](#CD012994-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Ivermectin 200 μg/kg (1 to 2 doses) versus permethrin 5% lotion (1 to 5 applications), Outcome 2 Complete clearance ‐ week 2.2Risk Ratio (M‐H, Random, 95% CI)Subtotals only2.1 IVER 1 dose versus PER 1 application1120Risk Ratio (M‐H, Random, 95% CI)1.0 \[0.78, 1.29\]2.2 IVER 2 doses versus PER on 5 consecutive nights1107Risk Ratio (M‐H, Random, 95% CI)0.97 \[0.81, 1.17\][3 Number of participants with ≥ 1 adverse event ‐ week 2](#CD012994-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Ivermectin 200 μg/kg (1 to 2 doses) versus permethrin 5% lotion (1 to 5 applications), Outcome 3 Number of participants with ≥ 1 adverse event ‐ week 2.1100Risk Ratio (M‐H, Random, 95% CI)5.00 \[0.25, 101.58\][4 Withdrawal due to adverse event ‐ week 2](#CD012994-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Ivermectin 200 μg/kg (1 to 2 doses) versus permethrin 5% lotion (1 to 5 applications), Outcome 4 Withdrawal due to adverse event ‐ week 2.1120Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\]

Comparison 3Ivermectin 200 μg/kg (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Complete clearance ‐ week 1](#CD012994-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Ivermectin 200 μg/kg (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications), Outcome 1 Complete clearance ‐ week 1.162Risk Ratio (M‐H, Random, 95% CI)0.84 \[0.65, 1.08\][2 Complete clearance ‐ week 2](#CD012994-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Ivermectin 200 μg/kg (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications), Outcome 2 Complete clearance ‐ week 2.162Risk Ratio (M‐H, Random, 95% CI)1.0 \[0.94, 1.06\][3 Complete clearance ‐ week 4](#CD012994-fig-00303){ref-type="fig"}Analysis 3.3Comparison 3 Ivermectin 200 μg/kg (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications), Outcome 3 Complete clearance ‐ week 4.2272Risk Ratio (M‐H, Random, 95% CI)0.99 \[0.95, 1.03\][4 Number of participants with ≥ 1 adverse event ‐ week 4](#CD012994-fig-00304){ref-type="fig"}Analysis 3.4Comparison 3 Ivermectin 200 μg/kg (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications), Outcome 4 Number of participants with ≥ 1 adverse event ‐ week 4.1201Risk Ratio (M‐H, Random, 95% CI)5.05 \[0.25, 103.87\][5 Withdrawal due to adverse event ‐ week 4](#CD012994-fig-00305){ref-type="fig"}Analysis 3.5Comparison 3 Ivermectin 200 μg/kg (1 to 3 doses) versus ivermectin 1% lotion/solution (1 to 3 applications), Outcome 5 Withdrawal due to adverse event ‐ week 4.162Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\]

Comparison 4Ivermectin 1% lotion (1 to 3 applications) versus permethrin 5% cream (1 to 3 applications)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Complete clearance ‐ week 4](#CD012994-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Ivermectin 1% lotion (1 to 3 applications) versus permethrin 5% cream (1 to 3 applications), Outcome 1 Complete clearance ‐ week 4.1210Risk Ratio (M‐H, Random, 95% CI)1.02 \[0.96, 1.08\][2 Number of participants with ≥ 1 adverse event ‐ week 4](#CD012994-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Ivermectin 1% lotion (1 to 3 applications) versus permethrin 5% cream (1 to 3 applications), Outcome 2 Number of participants with ≥ 1 adverse event ‐ week 4.1200Risk Ratio (M‐H, Random, 95% CI)0.33 \[0.01, 7.93\]

Comparison 5Ivermectin 200 μg/kg (1 dose) versus ivermectin 200 μg/kg (2 doses)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Complete clearance ‐ week 4](#CD012994-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Ivermectin 200 μg/kg (1 dose) versus ivermectin 200 μg/kg (2 doses), Outcome 1 Complete clearance ‐ week 4.180Risk Ratio (M‐H, Random, 95% CI)0.97 \[0.83, 1.14\]

We have changed the secondary outcome 'number of patients requiring re‐treatment\' to 'number of participants re‐treated\'. We found this to be a more suitable outcome measure considering our research question.

In case of inconsistent or implausible outcome data within a publication, we asked the corresponding author for clarification, irrespective of the date of publication.

We clarified in the [Types of participants](#CD012994-sec3-0004){ref-type="sec"} section that we only included studies investigating people with classical scabies.

Characteristics of included studies \[ordered by study ID\] {#CD012994-sec2-0022}
===========================================================

[@CD012994-bbs2-0001]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 7 months, from November 2012 to May 2013Participants**Inclusion criteria**\
Aged 5 to 50 yearsClinical presentation of scabies: people experiencing itching and had characteristic lesions (that is, burrows, vesicles, papules, nodules or pustules) on anatomical sites of predilection for scabies (that is, the interdigital folds of the hands, the elbows, the wrists, the buttocks, the axillary folds, the nipple areolas in women and the male external genitalia); detailed physical and dermatological examination was done including description of the lesions and their distribution on the body and assessment of the degree of pruritusIdentification of a mite: parasitological examination of lesions was performed by low‐power microscopy; at least 4 to 6 scrapings per participant from separate locations were obtained, placed in a drop of 10% potassium hydroxide solution on a glass slide, and examined for the presence of living *Sarcoptes scabiei* (that is, adult forms), eggs, or faecal pellets\
**Exclusion criteria**\
Pregnant or lactating womenBody weight less than 15 kgPeople with a systemic condition such as abnormal liver and kidney functions, known thyroid disease, cardiac disorders, nervous system disorders and psychiatric illnessesPeople with history of diabetes mellitus, hypertension, or chronic infectious diseasesPeople having any other associated skin disease that could alter the picture of scabiesImmunocompromised individualsAtypical presentations like crusted scabiesPeople with any antiscabietic treatment in the preceding month\
**Baseline characteristics** (n = 50 completers in each group)\
Age (mean ± SD): group A: 27.84 ± 9.46, B: 25.28 ± 13.73, C: 22.52 ± 12.77, D: 28.40 ± 13.42Males/females: group A: 26/24, B: 14/36, C: 24/26, D: 20/30InterventionsA: Oral ivermectin 200 μg/kg body weight at day 1 and 7, taken with meals; tablets were taken in the presence of the physician (n = 53 participants)\
B: Permethrin 2.5% (for children below 10 years) or 5% (for adults) lotion applied by participant and left overnight to the whole body below neck for 5 consecutive nights (n = 54 participants)\
Not included in this review:\
C: Benzyl benzoate 20% cream applied by participant and left overnight to the whole body below neck for 5 consecutive nights (n = 55 participants)\
D: Sulfur ointment, 5% (for children below 10 years) or 10% (for adults) applied by participant and left overnight to the whole body below neck for 5 consecutive nights (n = 54 participants)\
Participants were first treated from secondary bacterial infection, if present, with azithromycin once daily for 3 days.Cured participants were prescribed antihistaminic for symptomatic treatment of remaining pruritus and/or nodules, and the uncured participants were prescribed repeated intervention along with antihistaminic.Members of the same family not enrolled in the study were given the same drugs according to their age or any other suitable regimen.OutcomesComplete cure (negative parasitological examination of the participant with complete absence of new lesions; residual and all new lesions were scraped for detection of mites; if only 1 mite was detected, this was considered as treatment failure; week 1 and 2)Number of participants re‐treated (week 1)Number of participant with ≥ 1 adverse eventFunding sourceQuote (page 478): \"This research was funded by authors themselves, and received support From Faculty of Medicine Fayoum University.\"Declarations of interestQuote (page 478): \"The authors report no conflicts of interest.\"NotesLocation: Al Fayoum, Egypt\
Clinical trial registry: PACTR201505001116484***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote (page 474): \"random allocation number generated through computer\"Allocation concealment (selection bias)Low riskQuote (page 474): \"randomly allocated\"\
Quote from Pan African Clinical Trials Registry: \"Sealed opaque envelopes\"Blinding of participants and personnel (performance bias) EfficacyHigh riskQuote from Pan African Clinical Trials Registry: \"Open‐label (masking not used)\"Blinding of participants and personnel (performance bias) SafetyHigh riskQuote from Pan African Clinical Trials Registry: \"Open‐label (masking not used)\"Blinding of outcome assessment (detection bias) EfficacyHigh riskQuote from Pan African Clinical Trials Registry: \"Open‐label (masking not used)\"Blinding of outcome assessment (detection bias) SafetyHigh riskQuote from Pan African Clinical Trials Registry: \"Open‐label (masking not used)\"Incomplete outcome data (attrition bias) EfficacyLow risk16/216 participants lost to follow‐up (permethrin group: 4; oral ivermectin group: 3; benzoyl benzoate group: 5; sulfur group: 4)\
No intention‐to‐treat analysis performed.\
Quote (page 475, Figure 1)Incomplete outcome data (attrition bias) SafetyLow risk16/216 participants lost to follow‐up (permethrin group: 4; oral ivermectin group: 3; benzoyl benzoate group: 5; sulfur group: 4)\
Quote (page 475, Figure 1)Selective reporting (reporting bias)Unclear riskOutcomes stated in Pan African Clinical Trials Registry, but registration was on 25 April 2015 (after completion of study).Other biasUnclear risk‐[@CD012994-bbs2-0002]MethodsSingle‐centre, randomized trial\
Duration: not statedParticipants**Inclusion criteria**\
Age ≥ 5 years and \> 15 kg body weightClinically and laboratory diagnosed scabies:Clinical diagnosis was based on the presence of ≥ 3 out of 4 criteria: nocturnal pruritus, family history of similar illness, clinical demonstration of burrows, scabies lesions at typical sitesLaboratory diagnosis: demonstration of mites and/or mite products (eggs, larva, or faecal pellets) in scrapings from skin lesions (burrows or scabetic papules from classical sites) using light microscopy after incubation in 15% potassium hydroxide\
**Exclusion criteria**\
Pregnant and lactating womenPeople with crusted (Norwegian) scabiesPeople with history of epileptic fits, immunodeficiency, secondary cutaneous infection or eczematization, and coexisting skin disease that could interfere with treatment evaluationPeople with history of recent scabetic treatmentKnown hypersensitivity to ivermectin\
**Baseline characteristics**\
Age (mean ± SD): 21.8 ± 15Males/females: 26/36InterventionsA: Ivermectin 1% solution applied once to entire body below neck at night (n = 32 participants)\
B: Oral ivermectin 200 μg/kg body weight after food on day 1 (n = 30 participants)\
Treatment was repeated after 1 week only in participants with persistent symptoms.Treatment of contacts and proper hygienic measures were emphasized.OutcomesCure ('effective\' = marked to excellent improvement in pruritus (score 0) and no lesions, absence of mites and their products on microscopy; score: 0 = no pruritus, no skin lesions; 1 = mild pruritus, ≤ 10 lesions; 2 = moderate pruritus, 11 to 49 lesions; 3 = marked pruritus, ≥ 50 lesions; week 1, 2, and 4)Number of participants withdrawn from study due to adverse eventFunding sourceNot statedDeclarations of interestNot statedNotesLocation: Minia, Egypt***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote (page 59): \"adaptive biased‐coin randomization"Allocation concealment (selection bias)Unclear riskInsufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskNo informationBlinding of participants and personnel (performance bias) SafetyHigh riskNo informationBlinding of outcome assessment (detection bias) EfficacyHigh riskNo informationBlinding of outcome assessment (detection bias) SafetyHigh riskNo informationIncomplete outcome data (attrition bias) EfficacyLow riskAll data reported, no loss to follow‐up.Incomplete outcome data (attrition bias) SafetyUnclear riskNo numerical data on participants with adverse events per study groupSelective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear risk‐[@CD012994-bbs2-0003]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 5 months, from March to July 2007Participants**Inclusion criteria**\
Above 12 years of ageNewly diagnosed with scabies (diagnosis was based on clinical symptoms and clinical history)Person had to satisfy ≥ 3 of following criteria: history of contact with a person with scabies, complaint of nocturnal itching, history of involvement of family members, presence of classical burrows on clinical examination, presence of typical scabetic lesions like papules, nodules, or vesicles\
**Exclusion criteria**\
Pregnant or lactating women; women of childbearing age or planning for conception in near futureAbnormal liver and kidney functions, known thyroid disease, cardiac disorders, nervous system disorders, and psychiatric illnesses; people with history of diabetes mellitus, hypertension, or chronic infectious diseasesAny concurrent medication for other illness, consuming tobacco in any form, alcohol, or any substance of abuseAny other associated skin disease that could alter the picture of scabiesKnown/suspected immunocompromised individualsScabies with atypical presentationsIntake of any antiscabetic treatment in the preceding weekNoncompliant participants\
**Baseline characteristics**\
Males/females: group A: 22/12, B: 18/16, C: 23/12InterventionsA: Permethrin 5% cream applied once to whole body below neck, left overnight (n = 34 participants)\
B: Oral ivermectin 200 μg/kg body weight as single dose, given as supervised medication along with printed handouts of "do\'s" in the local vernacular language (n = 34 participants)\
Same treatment was repeated if there were no signs of cure after 1 week.All participants were issued 25% benzyl benzoate lotion for topical application for family members and close contacts.\
Not included in this review:\
C: Benzyl benzoate 25% lotion applied to whole body below neck, left overnight, on 2 consecutive nights (n = 35 participants)OutcomesCure (no new lesions (papules, vesicles, and classical burrows), examined by dermatologist and principal investigator; week 1 and 2)Number of participants with ≥ 1 adverse eventFunding sourceNot statedDeclarations of interestNot statedNotesLocation: Nagpur, India***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"random allocation number generated through computer\"Allocation concealment (selection bias)Low riskQuote: \"number \[\...\] provided with any one of the chosen three therapeutic interventions\"Blinding of participants and personnel (performance bias) EfficacyHigh riskQuote: \"our study was biased due to nonblinding\"\
Not blindedBlinding of participants and personnel (performance bias) SafetyHigh riskQuote: \"our study was biased due to nonblinding\"\
Not blindedBlinding of outcome assessment (detection bias) EfficacyHigh riskQuote: \"our study was biased due to nonblinding\"\
Not blindedBlinding of outcome assessment (detection bias) SafetyHigh riskQuote: \"our study was biased due to nonblinding\"\
Not blindedIncomplete outcome data (attrition bias) EfficacyHigh risk23/103 participants lost to follow‐up (permethrin group: 6; oral ivermectin group: 7; benzyl benzoate group: 10)\
No intention‐to‐treat analysis performed.\
Quote: Table 1 and 2Incomplete outcome data (attrition bias) SafetyHigh risk23/103 participants lost to follow‐up (permethrin group: 6; oral ivermectin group: 7; benzyl benzoate group: 10)\
Quote: Table 1 and 2Selective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear risk‐[@CD012994-bbs2-0004]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 1 year and 8 months, from June 2007 to January 2009Participants**Inclusion criteria**\
Aged 5 to 80 yearsClinically diagnosed scabies:Microscopically diagnosed scabies (demonstration of egg, larvae, mite, or faecal material)In case of negative microscopic examination, person had to satisfy ≥ 3 of following criteria: presence of typical scabietic lesions (papules, nodules, or vesicles at classical sites), presence of classical burrows on clinical examination, nocturnal pruritus, history of involvement of family member or similar symptoms in contacts\
**Exclusion criteria**\
Pregnant women and lactating mothersPerson treated with any topical scabicidal therapy in the month before entryPeople taking any topical or systemic antibiotic therapy in the week before entry into the studyImmunologically compromised patientsHaving scabies with atypical presentation like crusted scabies or scabies incognitoPeople with secondary bacterial infectionHistory of allergy to any of the study drugsBlood pressure \< 100/60 mmHg\
**Baseline characteristics**\
Age (mean ± SD): group A: 23.40 ± 13.55, B: 21.97 ± 13.26, C: 22.52 ± 12.69Males/females: group A: 58/47, B: 58/47, C: 59/46InterventionsA: Permethrin 5% cream applied once to whole body covering neck to toe, left for ≥ 8 hours, along with printed information sheet in the local vernacular language (n = 105 participants)\
B: Oral ivermectin 200 μg/kg body weight as single dose, self administered along with printed information sheet in the local vernacular language (n = 105 participants)\
C: Ivermectin 1% lotion, left for ≥ 8 hours, along with printed information sheet in the local vernacular language, containing details regarding application of drug and other instructions (n = 105 participants)\
Participants who were not cured were prescribed repeat intervention along with antihistaminic at each follow‐up.Participants who were not cured at the end of 3rd week were switched over to standard treatment with 5% permethrin.All participants received oral hydroxyzine 10 mg or 25 mg twice daily for symptomatic treatment of pruritus.OutcomesClinical cure of scabietic lesions (no definition; week 1, 2, 3, and 4)Number of participants re‐treated (week 1, 2, 3, and 4)Number of participants with ≥ 1 adverse eventFunding sourceQuote: \"Source of Support: None\"Declarations of interestQuote: \"Conflict of Interest: None\"NotesLocation: Surendranagar, India***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"random allocation number generated through computer\"Allocation concealment (selection bias)Unclear riskInsufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskQuote: \"The study was open‐labeled.\", \"Possible variation, if any, due to different formulations‐ lotion and cream, cannot be ruled out.\"Blinding of participants and personnel (performance bias) SafetyHigh riskQuote: \"The study was open‐labeled.", "Possible variation, if any, due to different formulations‐ lotion and cream, cannot be ruled out.\"Blinding of outcome assessment (detection bias) EfficacyHigh riskQuote: \"The study was open‐labeled.", "Possible variation, if any, due to different formulations‐ lotion and cream, cannot be ruled out.\"Blinding of outcome assessment (detection bias) SafetyHigh riskQuote: \"The study was open‐labeled.\", \"Possible variation, if any, due to different formulations‐ lotion and cream, cannot be ruled out.\"Incomplete outcome data (attrition bias) EfficacyUnclear risk15/315 participants lost to follow‐up (permethrin group: 6; oral ivermectin group: 5; topical ivermectin group: 4)\
Quote: Figure 1\
No intention‐to‐treat analysis performed.\
Number of participants analysed in week 2 and 3 is unclear.Incomplete outcome data (attrition bias) SafetyLow risk15/315 participants lost to follow‐up (permethrin group: 6; oral ivermectin group: 5; topical ivermectin group: 4)\
Quote: Figure 1Selective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear risk‐[@CD012994-bbs2-0005]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: not statedParticipants**Inclusion criteria**\
At least 2 years of ageScabies (microscopic and clinical confirmation)\
**Exclusion criteria**\
Pregnant women\
**Baseline characteristics**\
Age: 3 to 71 (age 0 to 5: 9%, age 6 to 15: 22%, age 16 to 30: 22%, age 30 to 50: 9%, age ≥ 51: 7%; total does not equal 100%)Males/females: 140/60InterventionsA: Permethrin 5% cream overnight, single application from neck to toes in all family members (n = 50 participants)\
B: Oral ivermectin 200 μg/kg body weight d1 and d14 (n = 50 participants)\
Not included in this review:\
C: Gamma benzene hexachloride 1% for 2 consecutive overnight applications to all family members (n = 50 participants)\
D: White soft paraffin in a manner similar to group A (n = 50 participants)Outcomes\"Improvement clinically\" (no definition; week 4)Funding sourceQuote: \"Source of Support: None\"Declarations of interestQuote: \"Conflict of Interest: None\"NotesLocation: Kolkata, India\
We contacted first author twice via e‐mail but did not receive a response.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote: \"randomly distributed\"Allocation concealment (selection bias)Unclear riskInsufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskNo informationBlinding of participants and personnel (performance bias) SafetyHigh riskNo informationBlinding of outcome assessment (detection bias) EfficacyHigh riskNo informationBlinding of outcome assessment (detection bias) SafetyHigh riskNo informationIncomplete outcome data (attrition bias) EfficacyHigh riskPercentage of \"improved clinically\" reported, no definition.\
Results for groups C and D not reported.Incomplete outcome data (attrition bias) SafetyUnclear riskQuote: \"We however did not experience any adverse effect in all four groups.\"\
Unclear number of evaluated completersSelective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear risk‐[@CD012994-bbs2-0006]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 3 years, from January 1993 to December 1995Participants**Inclusion criteria**\
Scabies (indisputable, no information about methods of diagnosing scabies)No age limit\
**Exclusion criteria**\
Pregnant or lactating womenPeople with renal or hepatic insufficiencyPeople with antiscabietic treatment in 6 weeks prior to study\
**Baseline characteristics**\
Age (mean): group A: male: 12, female: 16; B: male: 18, female: 20Males/females: group A: 56/96, B: 53/32; unclear data, sum of males and females does not correspond to total number of included participantsInterventionsA: Oral ivermectin 250 μg/kg body weight on day 1 (n = 152 participants)\
B: Oral ivermectin 250 μg/kg body weight on day 1, 3, and 10 (n = 121 participants)\
9 participants in group A and 10 participants in group B with secondary infection received dicloxacillin 75 mg/kg body weight per day.95 healthy contacts received an oral single dose of 250 μg/kg body weight ivermectin.OutcomesCure (considerable improvement of dermatosis, no pruritus, no new lesions; up to 45 days)Funding sourceNot statedDeclarations of interestNot statedNotesLocation: Santiago Yancuitlalpan, Mexico***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote (page 179): \"patients were randomized in two groups\"Allocation concealment (selection bias)Unclear riskInsufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskQuote (page 179): \"An open therapeutic study\"\
Not blindedBlinding of participants and personnel (performance bias) SafetyHigh riskQuote (page 179): \"An open therapeutic study\"\
Not blindedBlinding of outcome assessment (detection bias) EfficacyHigh riskQuote (page 179): \"An open therapeutic study\"\
Not blindedBlinding of outcome assessment (detection bias) SafetyHigh riskQuote (page 179): \"An open therapeutic study\"\
Not blindedIncomplete outcome data (attrition bias) EfficacyHigh riskNo information on dropouts, unclear time point of evaluation, no absolute numbersIncomplete outcome data (attrition bias) SafetyHigh riskNo information on dropouts, unclear time point of evaluation, no absolute numbersSelective reporting (reporting bias)High riskNo data on defined outcomes such as pruritus, papules, excoriation, crusts, etc.Other biasUnclear risk‐[@CD012994-bbs2-0007]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 1 year, from April 2011 to March 2012Participants**Inclusion criteria**\
Age above 5 and below 60 yearsPeople of both sexesPeople willing to receive either topical or oral therapyPeople willing to follow‐up at 1st and 6th week or if any complaints in betweenScabies (no information about methods of diagnosing)\
**Exclusion criteria**\
Pregnant and lactating womenPeople who were not willing to come for follow‐upAny serious systemic illness\
**Baseline characteristics**\
Not statedInterventionsA: Oral ivermectin 200 μg/kg body weight, single dose (n = 60 participants)\
B: Permethrin 5% cream, single application below the jaw line after scrub bath and left overnight (n = 60 participants)\
Not included in this review:\
C: Gamma benzene hexachloride 1% lotion, single application (n = 60 participants)\
D: Benzyl benzoate 25% lotion, single application (n = 60 participants)OutcomesComplete improvement based on severity of pruritus or lesions (lesion count: \< 10 ‐ mild, 11 to 49 ‐ moderate, \> 50 ‐ severe; pruritus: 10‐centimetre visual analogue scale: 0 ‐ no pruritus, 1 to 3 ‐ mild, 4 to 6 ‐ moderate, 7 to 10 ‐ severe; week 1 and 6)Number of participants withdrawn from study due to adverse eventFunding sourceNot statedDeclarations of interestNot statedNotesLocation: Patna, India\
Children \"below 5y\" were excluded; unclear if children of 5 years of age were included or excluded.\
We contacted first author twice via e‐mail but did not receive a response.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote (page 1): \"simple random sampling\"\
Insufficient informationAllocation concealment (selection bias)Unclear riskQuote (page 2): \"randomly allocated\"\
Insufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskNo informationBlinding of participants and personnel (performance bias) SafetyHigh riskNo informationBlinding of outcome assessment (detection bias) EfficacyHigh riskNo informationBlinding of outcome assessment (detection bias) SafetyHigh riskNo informationIncomplete outcome data (attrition bias) EfficacyHigh riskQuote (page 2): Table/Fig‐1 ‐ Table/Fig‐5\
Results are reported for all 60 randomized participants per treatment group, but actual results of the outcomes scales are not reported; clear explanation of how 'improvement\' is reflected in the scales is missing.Incomplete outcome data (attrition bias) SafetyHigh riskQuote (page 1): \"The main objective of the study is to know the efficacy and safety of Oral Ivermectin in comparison to commonly used topical antiscabies drugs \[...\]\"\
Quote (page 3): \"Oral Ivermectin is well tolerated, non irritant to skin, does not show central nervous system side effects because it does not cross blood brain barrier.\"\
No information about safety issues in other treatment groups; no numerical data on safety were reportedSelective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear riskNo information on baseline data[@CD012994-bbs2-0008]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 10 months, from January to October 2011Participants**Inclusion criteria**\
Age was at least 12 yearsNewly diagnosed scabies: made on basis of history and clinical examination; presence of diffuse itching and visible lesions associated either with ≥ 2 typical locations of scabies (interdigital folds, flexor aspect of wrist and elbow, genitals, anterior axillary folds) or with a household member with itching\
**Exclusion criteria**\
Pregnant or lactating femalesAny history of diabetes, hypertension, or any chronic diseaseAny psychiatric illness or neurological disorder, any other associated skin disease which can affect the study due to same presentation like atopic dermatitis, dyshidrotic eczema, insect bite reaction, etc.\
**Baseline characteristics**\
Age (mean): group A: 23.55, B: 27.74, C: 28.89Males/females: group A: 49/21, B: 41/29, C: 51/19InterventionsA: Permethrin 5% cream on day 1 and 7, applied over whole body below neck and scrub bath taken 12 hours later (n = 70 participants)\
B: Oral ivermectin 200 μg/kg body weight on day 1 and 7, applied any time of day (n = 70 participants)\
Not included in this review:\
C: Gamma benzene hexachloride 1% lotion on day 1 and 7 applied over whole body below neck and scrub bath taken 12 hours later (n = 70 participants)\
Participants of group A and C were instructed to take warm‐water bath before application of medicine and then after application of medicine next morning.They were advised about also treating the family members and prevention of transmission by washing all clothes and bedding that came in contact.OutcomesComplete clinical cure (week 1 and 3; reduction in clinical grading score (up to grade 0 or 1) and itching grading score (up to grade 0, 1, or 2); \"moderate or good improvement\"):Clinical grading score: scale of 0 to 3: 0 = free of lesions (no lesions), 1 = 10 or fewer lesions (mild), 2 = 11 to 49 lesions (moderate), 3 = 50 or more lesions (severe)Itching grading score: participant was asked for reduction in pruritus, grading was done on given scale by the observer: scale of 0 to 4: 0 = 0% (no pruritus), 1 = 1% to 25% (mild pruritus), 2 = 26% to 50% (moderate pruritus), 3 = 51% to 75% (severe pruritus), 4 = 76% to 100% (very severe pruritusNumber of participants with ≥ 1 adverse eventFunding sourceQuote (page 15): \"Source of support: Nil\"Declarations of interestQuote (page 15): \"Conflict of interest: Nil\"NotesLocation: Jhansi, India***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote (page 16): \"randomly on basis of a computer generated random table\"Allocation concealment (selection bias)Unclear riskInsufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskQuote (page 15): \"open label\"Blinding of participants and personnel (performance bias) SafetyHigh riskQuote (page 15): \"open label\"Blinding of outcome assessment (detection bias) EfficacyHigh riskQuote (page 15): \"open label\"Blinding of outcome assessment (detection bias) SafetyHigh riskQuote (page 15): \"open label\"Incomplete outcome data (attrition bias) EfficacyHigh risk35/210 participants lost to follow‐up or non‐compliant (permethrin group: 8; oral ivermectin group: 12; GBH group: 15)\
Quote (page 18 and Table 2): \"several patients were lost during follow up\"\
No intention‐to‐treat analysis performed.Incomplete outcome data (attrition bias) SafetyHigh risk35/210 participants lost to follow‐up or non‐compliant (permethrin group: 8; oral ivermectin group: 12; GBH group: 15)\
Quote (page 18 and Table 2): \"several patients were lost during follow up\"Selective reporting (reporting bias)High riskCure (moderate or good improvement) and not cured (no or mild improvement) were defined but not reported.\
Assessment of safety was planned, but not reported numerically.Other biasUnclear risk‐[@CD012994-bbs2-0009]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: not statedParticipants**Inclusion criteria**\
Aged 2 to 60 yearsDiagnosed as having scabies on history and examination; scraping for mite was performed in cases of doubt\
**Exclusion criteria**\
Pregnant and lactating femalesImmunocompromised patientsPeople having bacterial, fungal, or viral infections of skinPeople receiving any treatment for systemic disordersPeople who received treatment for scabies in last 4 weeks\
**Baseline characteristics** (for completers only)\
Males/females: group A: 24/20, B: 20/22InterventionsA: Oral ivermectin 200 μg/kg body weight as a single dose (n = 44 participants completed)\
B: Permethrin 5% cream at night on whole body for 12 hours, single application (n = 42 participants completed)\
100 participants randomized, number of randomized participants per study group unclear.Non‐responders to first treatment were given second dose at second week in their respective group.OutcomesCure of disease (no lesions; week 1, 2, and 4)Number of participants re‐treated (week 2)Number of participants with ≥ 1 adverse eventFunding sourceNot statedDeclarations of interestNot statedNotesLocation: Lahore, Pakistan\
Probably baseline differences: page 229: \"more patients in the ivermectin group had moderate and severe lesions as compared to permethrin group\"\
We contacted first author twice via e‐mail but did not receive a response.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"divided by using random number table into group A and group B\"Allocation concealment (selection bias)Unclear riskInsufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskNo informationBlinding of participants and personnel (performance bias) SafetyHigh riskNo informationBlinding of outcome assessment (detection bias) EfficacyHigh riskNo informationBlinding of outcome assessment (detection bias) SafetyHigh riskNo informationIncomplete outcome data (attrition bias) EfficacyHigh risk14/100 participants lost to follow‐up (unclear how many in each group, probably 6 in ivermectin group, 8 in permethrin group)\
Quote: \"14 participants lost to follow up\"\
No intention‐to‐treat analysis performed; number of randomized participants per study group unclear.Incomplete outcome data (attrition bias) SafetyHigh risk14/100 participants lost to follow‐up (unclear how many in each group, probably 6 in ivermectin group, 8 in permethrin group)\
Quote: \"14 participants lost to follow up\"\
Unclear number of randomized participants per study groupSelective reporting (reporting bias)Unclear riskInsufficient informationOther biasHigh riskSex distribution in Table 1 seems to be reversed.\
Probably baseline differences in severity: \"more patients in the ivermectin group had moderate and severe lesions as compared to permethrin group\"\
Inconsistent data for safety (page 229 and 300): 8 versus 7 participants with adverse events[@CD012994-bbs2-0010]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 1 year and 7 months, from November 2011 to May 2013Participants**Inclusion criteria**\
Aged 5 to 15 yearsNewly diagnosed with scabiesDiagnosed by dermatologist: people with severity score 1, 2, or 3 were eligible; assessed by counting the number of lesions and assigning a score: 0 (free of lesions ‐ no scabies), 1 (10 or fewer lesions ‐ mild), 2 (11 to 49 lesions ‐ moderate), 3 (50 or more lesions ‐ severe), 4 (crusty ‐ very severe)Diagnosis confirmed by microscopic examination of mite in \"many patients\", by biopsy of the skin lesions in \"few patients\"Body weight \> 15 kg\
**Exclusion criteria**\
Abnormal liver and kidney functions, known thyroid disease, cardiac disorders, nervous system disorders, psychiatric illnesses; people with history of diabetes mellitus, hypertension, or infectious diseasesAny concurrent medication for other illnessAny other associated skin disease that could alter the picture of scabies, or complications of scabies like pyodermaKnown/suspected immunocompromised individuals or parents diagnosed as HIV, having scabies with atypical presentationsIntake of any antiscabetic treatment in the preceding 4 weeksIntake of topical steroid in the previous 4 weeksKnown hypersensitivity to oral or topical preparationsPeople whose family/household members or classmates have scabies at the same timeNoncompliant people/guardians\
**Baseline characteristics**\
Males/females: group A: 31/19, group B: 30/20Age (mean): group A: 10.5, group B: 9.6InterventionsA: Permethrin 5% cream, single application to whole body below neck, left overnight (n = 50 participants)\
B: Oral ivermectin 200 μg/kg body weight as a single dose (n = 50 participants)\
All participants were given antipruritic or antihistaminic medication for pruritus.Participants who showed no signs of cure at first follow‐up were given same treatment again only once.All family contacts received same treatment as the study participant (children \< 5 years of age and pregnant women were treated with 12.5% to 25% benzyl benzoate emulsion, supplied free of cost).OutcomesCure (absence of clinical lesions and no new lesions like papules, vesicles, and classical burrows suggestive of live parasite; week 1, 2, and 4)Number of participants re‐treated (week 1)Number of participants with ≥ 1 adverse eventFunding sourceNot statedDeclarations of interestNot statedNotesLocation: Bangalore, India\
Abstract available, and first author provided unpublished data (doctoral thesis); not all questions were answered by contact author.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote (doctoral thesis, page 42): \"Simple random sampling\"\
Insufficient informationAllocation concealment (selection bias)Unclear riskInsufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskQuote (abstract): \"open labelled\"Blinding of participants and personnel (performance bias) SafetyHigh riskQuote (abstract): \"open labelled\"Blinding of outcome assessment (detection bias) EfficacyHigh riskQuote (abstract): \"open labelled\"Blinding of outcome assessment (detection bias) SafetyHigh riskQuote (abstract): \"open labelled\"Incomplete outcome data (attrition bias) EfficacyLow risk4/100 participants lost to follow‐up (permethrin group: 2; oral ivermectin group: 2)\
Intention‐to‐treat analysis performed.Incomplete outcome data (attrition bias) SafetyLow risk4/100 participants lost to follow‐up (permethrin group: 2; oral ivermectin group: 2)Selective reporting (reporting bias)Unclear riskInsufficient informationOther biasHigh riskInconsistent data for male/female ratio (page 55/56: 61 males/39 females; page 76: 63 males/37 females)\
Inconsistent response data in abstract and doctoral thesis; conservative approach was followed[@CD012994-bbs2-0011]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: not statedParticipants**Inclusion criteria**\
Aged 18 to 60 yearsConfirmed diagnosis of scabies by burrow detection by ink method and microscopic evidence of *Sarcoptes scabiei* mite in any of its development stage or its faeces\
**Exclusion criteria**\
Pregnant or lactating womenHypersensitivity to permethrin or ivermectinPrior use of topical or systemic scabicide in last 4 weeksPeople on radiotherapy, steroids or other immunosuppressive drugs for any systemic or cutaneous indicationPeople with any chronic debilitating disorders, neoplasias, with neurological, hepatic, or renal dysfunction\
**Baseline characteristics**\
Age (mean ± SD): group A: 31.45 ± 9.78, B: 29.45 ± 9.72 (data from Table 1)InterventionsA: Permethrin 5% lotion form on whole body (from neck to toe) for 10 to 12 hours followed by a bath, single application; participants received explicit written instructions about topical application (n = 60 participants)\
B: Oral ivermectin 200 μg/kg body weight as a single dose, taken in the presence of the investigator (n = 60 participants)\
All participants were given antihistamines at bedtime during first week.Secondary infection, when present, was treated with a 7‐day course of antibiotic.Contacts of the participants of both groups were treated at the same time with same treatment (\< 5 years of age and pregnant or lactating women were treated with 5% to 10% sulphur ointment).OutcomesCure (no itching, cutaneous lesions/burrows, and microscopy; week 1 and 2)Number of participants withdrawn from study due to adverse eventFunding sourceNot statedDeclarations of interestNot statedNotesLocation: Lahore, Pakistan\
Statistically significant baseline differences: page 47: \"history of scabies in contacts was present more in group A than in group B\"\
Inconsistent data for mean age in abstract and Table 1\
We contacted author for more details to assess risk of bias.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"randomly divided\"\
Author confirmed via e‐mail: \"random number table\"Allocation concealment (selection bias)Low riskAuthor confirmed via e‐mail: \"assignment by nurse, treated by physician blind to assignment\"Blinding of participants and personnel (performance bias) EfficacyLow riskAuthor confirmed via e‐mail: \"treated by physician blind to assignment\"Blinding of participants and personnel (performance bias) SafetyHigh riskProbably not blindedBlinding of outcome assessment (detection bias) EfficacyLow riskAuthor confirmed via e‐mail: \"treated by physician blind to assignment\"Blinding of outcome assessment (detection bias) SafetyHigh riskProbably not blindedIncomplete outcome data (attrition bias) EfficacyLow riskQuote: \"All 120 patients completed the study.\"Incomplete outcome data (attrition bias) SafetyLow riskQuote: \"All 120 patients completed the study.\"Selective reporting (reporting bias)Unclear riskInsufficient informationOther biasHigh riskInconsistent data for mean age in abstract and Table 1\
Statistically significant baseline differences: page 47: \"history of scabies in contacts was present more in group A than in group B\"[@CD012994-bbs2-0012]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 1 year and 4 months, from December 2006 to March 2008Participants**Inclusion criteria**\
Age over 5 years and/or \> 15 kgClinically diagnosed scabies: demonstration of eggs, larva, mites/mite products, or faecal pellets by light microscopy in the scrapings from multiple representative or suspected skin lesions in 10% potassium hydroxide and/or the presence of ≥ 3 of the following clinical criteria: demonstration of burrow; presence of scabetic lesions at the classical sites; nocturnal pruritus; family history of similar illness\
**Exclusion criteria**\
Pregnant and lactating womenPeople with immunodeficiency or severe systemic disease or with heavily crusted or nodular lesions, secondary infection or eczematization and coexisting dermatological disease that could interfere with the diagnosis and subsequent monitoring of scabiesAntiscabetic or topical steroid in the previous 4 weeksKnown hypersensitivity to the trial drugs\
**Baseline characteristics**\
Age (mean ± SD): group A: 21.38 ± 13.17, B: 23.40 ± 11.03, C: 23.53 ± 12.73Males/females: group A: 19/21, B: 29/11, C: 24/16InterventionsA: Permethrin 5% cream, self applied on day 1 and placebo tablets of vitamin B‐complex on day 1 and 15 (n = 40 participants)\
B: Placebo cream, self applied on day 1 and oral ivermectin 200 μg/kg body weight on day 1 and placebo tablet of vitamin B‐complex on day 15 (n = 40 participants)\
C: Placebo cream, self applied on day 1 and oral ivermectin 200 μg/kg body weight on day 1 and 15 (n = 40 participants)\
Participants were instructed to apply the medication all over the body below the neck at night.All family contacts were provided with permethrin 5% cream for single overnight application, free of cost.OutcomesComplete clinical cure (defined as reduction in both the number of lesions as well as the grade of pruritus by more than or equal to 50% (that is, moderate and good improvement) and negative microscopy; week 1, 2, and 4)Number of participants with ≥ 1 adverse event (data for group B and C combined)Funding sourceNot statedDeclarations of interestNot statedNotesLocation: New Delhi, India***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"computer‐generated random numbers\"Allocation concealment (selection bias)Low riskQuote: \"dispensed by a trained staff nurse in identical pre‐coded and numbered container\"Blinding of participants and personnel (performance bias) EfficacyLow riskQuote: \"placebos were similar to the trial drugs in color, shape, size, and consistency and were dispensed by a trained staff nurse in identical pre‐coded and numbered container\"Blinding of participants and personnel (performance bias) SafetyLow riskQuote: \"placebos were similar to the trial drugs in color, shape, size, and consistency and were dispensed by a trained staff nurse in identical pre‐coded and numbered container\"Blinding of outcome assessment (detection bias) EfficacyLow riskQuote: \"neither the investigator nor the patients were aware of the composition of drugs allocated and the code was revealed only after the completion of the study\"Blinding of outcome assessment (detection bias) SafetyLow riskQuote: \"neither the investigator nor the patients were aware of the composition of drugs allocated and the code was revealed only after the completion of the study\"Incomplete outcome data (attrition bias) EfficacyLow risk3/120 participants lost to follow‐up (permethrin group: 2; oral ivermectin ‐ 2 doses group: 1)\
No withdrawal at 1 week follow‐up; no intention‐to‐treat analysis for week 2 and 4Incomplete outcome data (attrition bias) SafetyUnclear risk3/120 participants lost to follow‐up (permethrin group: 2; oral ivermectin ‐ 2 doses group: 1)\
Number of adverse events reported for ivermectin groups were combined.Selective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear risk‐[@CD012994-bbs2-0013]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 1 year and 5 months, from August 1996 to December 1997Participants**Inclusion criteria**\
Older than 5 years of ageScabies: diagnosed by the demonstration of eggs, larva, mites, or faecal pellets by light microscopy or by the presence of ≥ 3 of the following clinical criteria confirmed independently by 2 consultants: demonstration of burrow, presence of scabietic lesions at the classical sites, nocturnal pruritus, family history of similar illness\
**Exclusion criteria**\
Pregnant and lactating womenAny antiscabietic treatment in the previous monthPeople with serious central nervous system, hepatic, cardiac, or renal disease\
**Baseline characteristics**\
Age (mean ± SD): group A: 21.28 ± 13.44, B: 22.4 ± 12.6Males/females: group A: 26/14, B: 33/12InterventionsA: Oral ivermectin 200 μg/kg body weight, single dose, supervised (n = 40 participants)\
B: Permethrin 5% cream, single application overnight (n = 45 participants)\
All participants received standard instructions (about the mode of application, general measures, importance of treating the family contacts, prevention of fomite transmission).Participants with treatment failure (no improvement in pruritus and skin lesions, appearance of new lesions, or presence of mites or their products on microscopy) at week 2 received another dose of same treatment; at week 4 cross‐over to other group.Secondary infection was treated with a 7‐day course of erythromycin 250 mg 4 times daily.All family contacts received same treatment as the study participant (children \< 5 years of age and pregnant women were treated with 12.5% to 25% benzyl benzoate emulsion).OutcomesComplete clearance (good improvement; week 1, 2, 4, and 8)Number of participants re‐treated (week 2 and 4)Number of participants with ≥ 1 adverse eventNumber of participants withdrawn from study due to adverse eventFunding sourceNot statedDeclarations of interestNot statedNotesLocation: Trivandrum, India***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote (page 237): \"randomly allocated\"\
Insufficient informationAllocation concealment (selection bias)Unclear riskQuote (page 237): \"randomly allocated\"\
Insufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskNo informationBlinding of participants and personnel (performance bias) SafetyHigh riskNo informationBlinding of outcome assessment (detection bias) EfficacyHigh riskNo informationBlinding of outcome assessment (detection bias) SafetyHigh riskNo informationIncomplete outcome data (attrition bias) EfficacyLow riskNo missing outcome dataIncomplete outcome data (attrition bias) SafetyLow riskNo missing outcome dataSelective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear riskData for 'complete clearance\' reported in figure only; numerical data were extracted from chart for meta‐analysis.[@CD012994-bbs2-0014]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: not statedParticipants**Inclusion criteria**\
People with scabies\
**Exclusion criteria**\
Not stated\
**Baseline characteristics**\
Not statedInterventionsA: Permethrin 5% (type of formulation not stated; n = unclear)\
B: Oral ivermectin 200 μg/kg body weight as a single dose (n = unclear)\
100 participants were allocated.If there was no sign of cure, same treatment was repeated.OutcomesCure rate (no definition; time point of evaluation unclear)Funding sourceNot statedDeclarations of interestNot statedNotesLocation: Nanded, India\
Only abstract available\
We contacted first author twice via e‐mail but did not receive a response.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote: \"randomely allocated\"\
Insufficient informationAllocation concealment (selection bias)Unclear riskQuote: \"randomely allocated\"\
Insufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskNo informationBlinding of participants and personnel (performance bias) SafetyHigh riskNo informationBlinding of outcome assessment (detection bias) EfficacyHigh riskNo informationBlinding of outcome assessment (detection bias) SafetyHigh riskNo informationIncomplete outcome data (attrition bias) EfficacyHigh riskNo numerical data given.Incomplete outcome data (attrition bias) SafetyHigh riskNo numerical data given.Selective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear risk‐[@CD012994-bbs2-0015]MethodsSingle‐centre, parallel‐group randomized trial\
Duration: 1 year and 1 month, from March 2013 to March 2014Participants**Inclusion criteria**\
Age between 5 to 60 yearsNew patients of scabies as diagnosed by dermatologistHistory of involvement of family member or similar symptoms in contactsPresence of nocturnal itchingFor those whose microscopic examination was negative, inclusion in study was based on clinical criteria\
**Exclusion criteria**\
Pregnant and lactating womenPeople with any other associated skin disease that could alter the picture of scabies, or complications of scabies like pyodermaKnown or suspected immunocompromised individuals like HIVHistory of topical steroid use in the previous 4 weeks or use of topical or systemic antibiotic therapy in the week before entry into the studyReceived any antiscabetic treatment in the past 4 weeksNoncompliant participants or guardiansPeople not willing to come for follow‐upPeople having scabies with atypical presentation like crusted scabies or scabies incognitoHistory of allergy to any of the study drugsPeople with associated comorbid condition like hypertension, diabetes, liver, kidney disorder\
**Baseline characteristics**\
Age (mean ± SD): group A: 16.74 ± 9.90, B: 22.04 ± 10.61, C: 23.74 ± 9.91Males/females: group A: 30/20, B: 28/22, C: 29/21InterventionsA: Permethrin 5% cream, single application (n = 50 participants)\
B: Oral ivermectin 200 μg/kg body weight, single application (n = 50 participants)\
Not included in this review:\
C: Combination of topical permethrin with oral ivermectin (n = 50 participants)\
If there were no signs of cure, the same intervention was repeated at the end of week 1 only once.OutcomesCure (no new clinical lesions and improvement in pruritus, no new lesions like papules, vesicles, and classical burrows suggestive of live parasite should be seen; week 1 and 4)Number of participants with ≥ 1 adverse eventNumber of participants withdrawn due to adverse eventFunding sourceQuote (page 71): \"Funding: None\"Declarations of interestQuote (page 71): \"Conflict of interest: None declared\"NotesLocation: Nanded, India***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote (page 68): \"randomised\"\
Insufficient informationAllocation concealment (selection bias)Unclear riskQuote (page 69): \"randomly allocated\"\
Insufficient informationBlinding of participants and personnel (performance bias) EfficacyHigh riskQuote (page 68): \"open‐label\"Blinding of participants and personnel (performance bias) SafetyHigh riskQuote (page 68): \"open‐label\"Blinding of outcome assessment (detection bias) EfficacyHigh riskQuote (page 68): \"open‐label\"Blinding of outcome assessment (detection bias) SafetyHigh riskQuote (page 68): \"open‐label\"Incomplete outcome data (attrition bias) EfficacyLow riskNo missing outcome dataIncomplete outcome data (attrition bias) SafetyLow riskNo missing outcome dataSelective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear risk‐[^7]

Characteristics of excluded studies \[ordered by study ID\] {#CD012994-sec2-0023}
===========================================================

StudyReason for exclusion[@CD012994-bbs2-0016]No original data, same study population as in [@CD012994-bbs2-0004][@CD012994-bbs2-0017]Suspicion of flawed data Issue was presented and discussed at the annual meeting of the Cochrane Skin Group on 9‐10 January 2017 in Berlin: unanimous decision to exclude the study.[@CD012994-bbs2-0018]Suspicion of flawed data Issue was presented and discussed at the annual meeting of the Cochrane Skin Group on 9‐10 January 2017 in Berlin: unanimous decision to exclude the study.[@CD012994-bbs2-0019]Study of people with crusted scabies; not yet open for participant recruitment[@CD012994-bbs2-0020]Suspicion of flawed data Issue was presented and discussed at the annual meeting of the Cochrane Skin Group on 9‐10 January 2017 in Berlin: unanimous decision to exclude the study.

Characteristics of ongoing studies \[ordered by study ID\] {#CD012994-sec2-0024}
==========================================================

[@CD012994-bbs2-0021]Trial name or titleOral Ivermectin Versus Topical Permethrin to Treat Scabies in Children (SCRATCH)MethodsMulticentre, randomized trial Duration: 1 year and 9 months, from January 2016 to September 2017 (estimated)Participants**Inclusion criteria**\
Children up to 16 years of ageWeight \> 15 kgDocumented diagnosis of scabies, defined by positive dermoscopic examination\
**Exclusion criteria**\
Previous scabies therapy during the past 4 weeksKnown allergy to ivermectin or permethrinWidespread eczematization or impetiginizationLiver and renal failureInterventionsA: Permethrin 5% cream on day 1 and 10\
B: Oral ivermectin 200 μg/kg body weight on day 1 and 10\
Estimated enrolment: 502 participantsOutcomesAssessment of skin lesions and healing at day 28Starting dateJanuary 2016Contact informationFranck BORALEVI, Professor 05 56 79 59 41 franck.boralevi\@chu‐bordeaux.fr Fabienne NACKA, PhD 05 57 82 01 08 fabienne.nacka\@chu‐bordeaux.frStudy IDClinical trial registry: NCT02407782 Other study ID number: CHUBX 2011/16NotesLocation: Bordeaux, France Source: clinicaltrials.gov/ct2/show/NCT02407782 (last updated: 3 June 2016)

SR was the contact person with the editorial base, co‐ordinating the contributions from the co‐authors; sought additional information about papers; entered data into RevMan 5 ([@CD012994-bbs2-0076]); worked on the Methods section; updated the clinical sections of the Background based on the Cochrane Review 'Interventions for treating scabies\' by Mark Strong and Paul Johnstone ([@CD012994-bbs2-0088]). SR screened all hits using the inclusion/exclusion criteria; screened reference lists of included studies for additional randomized controlled trials; independently extracted data using the standardized form; performed the \'Risk of bias\' evaluation for all included trials; analysed and interpreted data; wrote the final draft of the review.

CD screened all hits using the inclusion/exclusion criteria and independently extracted data using the standardized form; performed the \'Risk of bias\' evaluation for all included trials. CD discussed data analysis strategies with SR and checked the data entered into Review Manager 5. CD also contributed substantially to writing the Cochrane Review.

SR and CD performed the GRADE assessment of all comparisons.

SR, CD, and AN jointly finalized the review. AN was solely responsible for the medical input and the '[Implications for practice](#CD012994-sec1-0008){ref-type="sec"}\' section.

Internal sources {#CD012994-sec2-0020}
================

Liverpool School of Tropical Medicine, UK.

External sources {#CD012994-sec2-0021}
================

Department for International Development (DFID), UK.Grant: 5242

SR and CD have no conflicts of interest. CD, SR, and AN previously published a systematic review on scabies treatments ([@CD012994-bbs2-0044]).

CD is a member of the Cochrane Scientific Committee.

AN is a member of the expert panel of the German consensus‐based guideline for the diagnosis and treatment of scabies published in January 2016 (AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.), Association of the Scientific Medical Societies in Germany; register number: 013‐052).

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^[@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0008]; [@CD012994-bbs2-0015]. ^2^Downgraded by 1 for serious risk of bias: assessed as moderate. ^3^Downgraded by 1 for serious imprecision: CI crosses minimal clinically important difference threshold: statistically significant difference of uncertain clinical importance. ^4^[@CD012994-bbs2-0013]; [@CD012994-bbs2-0003]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0010]. ^5^Downgraded by 1 for serious inconsistency: I² = 61% (P = 0.04). ^6^[@CD012994-bbs2-0012]. ^7^[@CD012994-bbs2-0013]; [@CD012994-bbs2-0009]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0010]; [@CD012994-bbs2-0015]. ^8^Downgraded by 1 for serious inconsistency: I² = 74% (P = 0.004). ^9^[@CD012994-bbs2-0003]. ^10^[@CD012994-bbs2-0009]; [@CD012994-bbs2-0012]; [@CD012994-bbs2-0004]; [@CD012994-bbs2-0015]. ^11^Downgraded by 1 for serious imprecision: CI crosses line of no effect and minimal clinically important difference thresholds: uncertain whether there is any difference. ^12^[@CD012994-bbs2-0013]; [@CD012994-bbs2-0007]; [@CD012994-bbs2-0015].

[^3]: ^1^[@CD012994-bbs2-0011]. ^2^Downgraded by 1 for serious risk of bias: assessed as moderate. ^3^[@CD012994-bbs2-0001]. ^4^Downgraded by 1 for serious imprecision: CI crosses line of no effect and minimal clinically important difference thresholds: uncertain whether there is any difference. ^5^Downgraded by 2 for very serious imprecision: CI crosses line of no effect and minimal clinically important difference thresholds: uncertain whether there is any difference and wide CI.

[^4]: ^1^[@CD012994-bbs2-0002]. ^2^Downgraded by 1 for serious risk of bias: assessed as moderate. ^3^Downgraded by 1 for serious imprecision: CI crosses line of no effect and minimal clinically important difference thresholds: uncertain whether there is any difference. ^4^[@CD012994-bbs2-0004]. ^5^Downgraded by 2 for very serious imprecision: CI crosses line of no effect and minimal clinically important difference thresholds: uncertain whether there is any difference and wide CI.

[^5]: ^1^[@CD012994-bbs2-0004]. ^2^Downgraded by 1 for serious risk of bias: assessed as moderate. ^3^Downgraded by 2 for very serious imprecision: CI crosses line of no effect and minimal clinically important difference thresholds: uncertain whether there is any difference and wide CI.

[^6]: ^1^[@CD012994-bbs2-0012].

[^7]: Abbreviations: GBH: gamma benzene hexachloride; SD: standard deviation.
